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An increasing number of cyclic dipeptides (CDPs) have been shown to exhibit important 
biological activity including antifungal, antibacterial, anticonvulsant and immunomodulatory 
activity.  Furthermore, some CDP derivatives have been shown to exhibit antitumour 
activity in vitro and in vivo.  Several proline-based CDPs that exhibit biological activity have 
been detected in various processed foods and beverages.  In the present study, the potential 
of seven proline-based CDPs to inhibit cancer cell growth was investigated in HT-29 
(colon), HeLa (cervical), MCF-7 (breast) and WHCO3 (oesophageal) cancer cell lines.  The 
CDPs used in this study were cyclo(Phe-Pro), cyclo(Tyr-Pro), cyclo(Gly-Pro), cyclo(Pro-
Pro), cyclo(His-Pro), cyclo(Leu-Pro) and cyclo(Thr-Pro). 
 
The sulforhodamine B (SRB) cell growth assay was used in an initial screening phase to 
investigate the effects of the CDPs in HT-29, HeLa and MCF-7 cells.  After exposing the 
cells to 10mM of the respective CDPs for 48 hours, the SRB assay results showed that only 
cyclo(Phe-Pro) exhibited more than 50% growth inhibition (p<0.01) in the three cell lines. 
The other CDPs showed comparatively marginal growth-inhibitory effects, except for 
cyclo(Tyr-Pro), which exhibited a pronounced effect in MCF-7 cells compared to HT-29 and 
HeLa cells.  The MTT assay was used to confirm the SRB assay results for cyclo(Phe-Pro) 
and cyclo(Tyr-Pro), extending the investigation to the use of the fourth cell line WHCO3 
and using a longer exposure time of 72 hours.  The MTT assay demonstrated a dose-
dependent (0.008-10 mM) growth inhibition by cyclo(Phe-Pro) with an IC50 value of 4.04 ± 
1.15 mM for HT-29 cells.  Cyclo(Phe-Pro) was subsequently used to investigate whether the 
growth-inhibitory effects of this CDP were related to the induction of apoptosis in HT-29 
cells.  Hoechst 33342 staining showed that 5mM cyclo(Phe-Pro) induced characteristic 
chromatin condensation and nuclear fragmentation in 18.3 ± 2.8% (p<0.01) of HT-29 cells 
after 72 hours.  Furthermore, annexin V binding revealed that HT-29 cells treated with 5 
mM cyclo(Phe-Pro) displayed phosphatidylserine externalization after 48 hours.  In addition, 
it was shown that 10 mM cyclo(Phe-Pro) induced poly(ADP-ribose)polymerase PARP 
cleavage, one of the hallmark events of apoptosis.  The use of the broad-range caspase 
inhibitor Z-VAD-FMK, showed that this PARP cleavage was caspase-dependent, which in 
turn was confirmed by demonstrating an increase in caspase-3 activity (p<0.01) in cyclo(Phe-
Pro)-treated HT-29 cells.  
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In conclusion, these findings demonstrate that cyclo(Phe-Pro) inhibited the growth of HT-
29, MCF-7, HeLa and WHCO3 cells, and induced apoptosis in HT-29 colon cancer cells, 
suggesting the potential antitumour activity of cyclo(Phe-Pro)-related CDPs.  
 
 
Keywords: cyclic dipeptides, cancer cells, growth inhibition, HT-29, apoptosis, PARP, 
caspase-3. 
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CHAPTER 1: LITERATURE REVIEW 
 
 
1.1  THE SIGNIFICANCE OF CONSTRAINED PEPTIDES  
 
There is a great diversity of biological roles played by peptides and proteins. This diversity is 
correlated with the many possibilities that exist for their primary sequences and three-
dimensional structures.  Some proteins, such as antibodies, cytokines, enzymes, clotting 
factors etc., are used as therapeutic agents in specific conditions (Rang et al., 1999).  Many 
small peptides are key factors in the regulation of a wide variety of biological functions, 
acting as hormones, neurotransmitters, or inhibitors (Rizo and Gierasch, 1992).  Small 
peptides have also been used therapeutically to treat various diseases such as hypertension, 
diabetes and cancer (Rang et al., 1999).   
 
The knowledge of the active conformation (three-dimensional structure) of a given 
polypeptide is a major step towards understanding its biological function.    Although many 
biophysical techniques exist to study polypeptide conformation, a major obstacle in the study 
of small peptides is their intrinsic flexibility, which allows for a large number of 
conformational possibilities (Deber et al., 1976).  One approach to reducing the number of 
conformational possibilities is to introduce cyclic constraints into a peptide.  Many biologically 
active peptides interact with multiple receptors, and constraining particular structural 
features can lead to drugs with high receptor specificity and less or no side effects.  The 
synthesis and study of constrained analogues has thus emerged as a powerful approach in 
peptide drug design (Rizo and Gierasch, 1992).   Furthermore, cyclopeptides are well known 
for their biological importance as antibiotics, toxins, hormones, or ion transport regulators 
(Ochinnikov and Ivanov, 1975).  The properties and biological diversity of the smallest 
cyclopeptides, namely cyclic dipeptides, are reviewed in Section 1.2.      
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1.2  CYCLIC DIPEPTIDES 
 
1.2.1 Diversity and Physicochemical Properties 
Cyclic dipeptides (CDPs) are also known as 2,5-dioxopiperazines, 2,5-diketopiperazines, 
cyclodipeptides, or dipeptide anhydrides.  The structure of a CDP shows that the 
diketopiperazine (DKP) ring is substituted by amino acid side chains (R1, R2) and that both 
peptide bonds are constrained in the cis-conformation (Figure 1.1).  The parent compound is 
cyclo(Gly-Gly) or c(Gly-Gly) in which R1 = R2 = H (Sammes, 1975).  X-ray crystallographic 
studies have shown that the substituted DKP ring exists in the planar conformation for 
molecules with a centre of symmetry [e.g. cyclo(Gly-Gly) and cyclo(Ala-Ala)], but buckled 
conformations of the ring occur for unsymmetrically substituted derivatives [e.g. cyclo(Gly-
Tyr) and cyclo(Pro-X) derivatives] (Davies and Khaled, 1976).    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  The structure of cyclic dipeptides (CDPs), bearing the diketopiperazine (DKP) nucleus, where R1 
and R2 are the side chains of amino acid residues of the respective CDPs. Taken from Sammes (1975). 
 
 
CDPs are among the most common peptide derivatives found in nature (Prasad, 1995).   
Many CDPs are endogenous to members of the animal and plant kingdoms, including 
marine sponges (e.g. Fu et al., 1998; Jayatilake et al., 1996; Adamsczeski et al., 1995) and fungi 
(Steyn, 1973) (see Table 1.1 for specific examples).  Cyclo(His-Pro) is the only CDP that has 
been conclusively shown to be endogenous to mammals (Takahara et al., 1983).  CDPs have 
been detected in protein and polypeptide hydrolysates as well as fermentation broths and 
cultures of yeasts, lichens, and fungi (Nagayama et al., 1990; Sammes, 1975; Bodanszky et al., 
1973; Atkins and Neilands, 1968; Brown et al., 1965; Johnson et al., 1951; Forster and 
Saviole, 1922).   
 
 
 
 1 2 
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Table 1.1  Simple cyclic dipeptides that occur naturally in the protist and plant kingdoms.                           
 
Diketopiperazine      Species          Common Name     
        
   
Cyclo(Pro-Leu)†   Rosellinia necatrix                  Fungus          
     Aspergillus fumigatus               Fungus          
Cyclo(Pro-Val)   Rosellinia necatrix                   Fungus          
     Aspergillus ochraceus                Fungus          
     Metarrhizum ansiopha                  Fungus (mould)         
Cyclo(Pro-Phe)   Rosellinia necatrix                            Fungus          
Cyclo(Pro-Tyr)   Alternaria alternata                Fungus        
Cyclo(Pro-Trp)   Penicillium brevicompactum        Fungus (mould) 
Cyclo(Phe-Phe)   Penicillium nigricans   Fungus (mould) 
     Streptomyces noursei 
Cyclo(Ala-Leu)   Aspergillus niger   Fungus (black mould) 
          
        Adapted from Prasad (1995) 
            † All amino acids are in the L configuration 
 
 
CDPs have also been detected in a variety of processed foods and beverages, including 
various cereal grains (Dansi et al., 1970), cocoa (Rizzi, 1989), Comte cheese (Roudot-Algaron 
et al., 1993), hydrolysed vegetable protein (Eriksen and Fagerson, 1980), aged sake 
(Takahashi et al., 1974), dried squid (Kawai et al., 1991), beer (Gautschi and Schmid, 1997) 
and roasted coffee (Ginz and Engelhardt, 2000).  Several CDPS were found to contribute to 
the perceived bitterness among some of the processed foods and beverages listed above.  
Gautschi and Schmid (1997) studied a marketplace cross-section of five commercial beers, 
manufactured in different countries, and reported cyclo(Phe-Pro) to be the most prominent 
CDP, present at concentrations up to 0.25 mM.   
 
 
1.2.2  Biologically Active CDPs and CDP Derivatives 
Many of these compounds have been regarded as important metabolic intermediates with 
significant biological activity, rather than as protein artefacts (Prasad, 1995).  An increasing 
number of CDPs and other DKP-type compounds have been shown to exhibit important 
physiological and/or pharmacological activities.  A broad spectrum of biological activity 
exhibited by various cyclic dipeptides is summarized in Table 1.2.  
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Table 1.2  Specific examples of biological activity exhibited by cyclic dipeptides 
 
 
Activity                       Cyclic Dipeptide                      Reference 
  
 
Immunomodulation        cyclo(Arg-Lys), cyclo(Asp-Lys)          Blažíčková et al., 1994 
 
Modulation of Glucose Metabolism       cyclo(His-Pro)                            Hwang et al., 2003 
 
Hormonal Regulation        cyclo(His-Pro)               Fragner et al., 1997 
 
Anticonvulsant            cyclo(Gly-Phe), cyclo(Ala-Phe)          Szkaradzinska et al.,  
            1994 
 
Antifungal         cyclo(Phe-Pro)               Ström et al.,  2002 
          cyclo(Trp-Pro), cyclo(Trp-Trp)          Graz et al., 1999 
 
Antibacterial         cyclo(Trp-Trp), cyclo(Trp-Pro),            Graz et al., 1999 
          cyclo(Phe-Pro), cyclo(Tyr-Pro)         
 
Inhibition of Cell Division        Dehydro derivatives of                  Kanzaki et al., 2000 
          cyclo(Phe-Phe)      
 
Inhibition of Dietary Fat Intake       cyclo(Asp-Pro)                 Lin et al., 1994 
 
Induction of Differentiation       cyclo(Phe-Pro), cyclo(Tyr-Pro),           Graz et al., 2000  
in Cancer Cell Lines        cyclo(Pro-Pro), cyclo(Trp-Pro)   
 
Molecular Recognition        cyclo(Gly-Leu), cyclo(Leu-Leu)           Christofaro and  
by Peptide Hosts†                      Chamberlin, 1994 
 
† Enantioselective and Diastereoselective Molecular Recognition of Cyclic Dipeptides by a C2             
  Macrolactam Host 
 
 
1.2.3  Proline-containing CDPs 
Proline is found frequently in naturally occurring biologically active peptides, including 
peptide hormones such as angiotensin and bradykinin, peptide antibiotics such as gramicidin S and 
actinomycin, and the peptide antitoxin, antamanide (Young et al., 1976).  The presence of 
proline in cyclic peptide sequences further reduces the number of possible conformational 
states, since the proline side chain severely restricts rotations about the N–Cα bond and 
limits the rotation of neighbouring groups (Deber et al., 1976).  Since proline and glycine 
residues often comprise much of the amino acid sequence in turn regions of secondary 
structure in proteins, it is perhaps no coincidence that peptide chains that contain proline 
and glycine have a higher probability of undergoing cyclization (Kopple, 1972).   
 
A large number of proline-based CDPs occur naturally in the plant and protist kingdoms 
(Table 1.1).  Several such CDPs have also been detected in fermentation broths and 
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processed foods and beverages as listed in section 1.2.1.  In many of the instances where 
CDPs have been detected, one of the constituent amino acids is proline.  Rizzi (1989) carried 
out model studies of DKP formation in cocoa and concluded that the mechanism involved 
intramolecular cyclization of linear peptide precursors.  Since dipeptides containing a proline 
or a hydroxyproline residue exhibit a marked propensity for intramolecular cyclization 
(Smith and Bergman, 1944), it is perhaps not surprising that several proline-based CDPs are 
detected in fermented and thermally treated foods.  In addition, the thermal treatment of 
food appears to favour the preservation of some amino acids compared to others.  For 
example, during the roasting of coffee beans there is a reduction in the amount of amino 
acids by 20-40%.  The content of reactive amino acids such as lysine is strongly decreased, 
whereas others such as proline or phenylalanine remain nearly unchanged (Ginz and 
Engelhardt, 2000). 
 
In addition to their widespread occurrence and interesting physicochemical properties, a 
considerable number of proline-based CDPs have the ability to affect important biological 
processes (Table 1.2).  For example cyclo(Tyr-Pro) and cyclo(Phe-Pro) have been implicated 
in the induction of gastrointestinal differentiation in HT-29 colon cancer cells, suggesting a 
potential antitumour activity (Graz et al., 2000).   
 
1.2.4 Absorption and Metabolism of CDPs 
The intestinal H+/oligopeptide cotransporter (PEPT1), which actively transports 
oligopeptides (Fei et al., 1994; Tamai et al., 1994), also transports several drugs including 
cephadroxil and cephalexin (Mizuma et al., 2002).  Mizuma et al. (1997) showed that 
cyclo(Gly-Phe) is much more stable than linear Gly-Phe, and can be transported by PEPT1 
in isolated rat small intestine without degradation by intestinal peptidases.  Differentiated 
Caco-2 cells express PEPT1 and are used as an in vitro model of the intestinal mucosa.  
Mizuma et al. (2002) found that some CDPs are actively transported in Caco-2 cell 
monolayers by PEPT1.  In contrast to the studies of Mizuma et al. (2002), Tamura et al. 
(1996) have shown that from a selected group of CDPs, cyclo(Ala-Lys) was only partially 
transported by PEPT1 while cyclo(Asp-Asp) and cyclo(Ala-Ala) permeate Caco-2 cell 
monolayers by passive diffusion, primarily via a paracellular route.  It has been shown that 
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some CDPs are rapidly transformed by rat cytochrome P450 3A to mono- or dihydroxylated 
metabolites.  This metabolism occurs in eight species including man and these interactions 
have only minor consequences in terms of P450 3A binding and metabolism of classical 
P450 3A substrates (Delaforge et al., 2001).   
 
1.2.5  CDPs and Cancer 
In addition to the biological activities discussed in section 1.2.2, a few CDP derivatives have 
been shown to exhibit potent antitumour activity.  One of the most unusual members of the 
family of simple DKPs is the antitumour agent compound 593 A (Figure 1.2).  The 
compound was isolated from Streptomyces griseoluteus as part of a general screening for new 
antitumour agents from microbial sources.  The compound possesses the β-chloramine 
function of the nitrogen mustards, a group of compounds whose derivatives have been 
incorporated into many synthetic drugs used in cancer chemotherapy (Sammes, 1975). 
 
 
 
 
Figure 1.2  The structure of the antitumour agent, compound 593 A.  Taken from Sammes (1975). 
 
Phenylahistin (Figure 1.3), a fungal CDP metabolite composed of phenylalanine and 
isoprenalated dehydrohistidine exhibits potent in vitro and in vivo antitumour activity (Kanoh 
et al., 1999).  Verticillin A, an antibiotic isolated from Verticillium spp. has been identified as an 
antitumour agent (Katagiri et al., 1970).  With the hundreds of CDP derivatives that can be 
found in nature (Sammes 1975), it is reasonable to speculate that there may be many more 
that possess antitumour activity. 
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Figure 1.3  The structure of phenylahistin. * (+) and (–) enantiomers.  Taken from Kanoh et al. (1999).  
 
 
 
1.3  THE SIGNIFICANCE OF CANCER AS A DISEASE  
 
Cancer is one of the major causes of death in the developed nations.  At least one in five of 
the human population of Europe and North America can expect to die of cancer (Alberts et 
al., 1994).  In South Africa, between the years 1993 and 1995, a total of 149 815 new cancer 
cases were reported to the National Cancer Registry (NCR), an average of 49 939 cases per 
year (Sitas et al., 1998).    
 
The nature of the disease and its prevalence have spurred the development of large cancer-
research institutes in many countries.  Vast funding has been made available by private 
agencies and pharmaceutical industries in an effort to find curative drugs and new measures 
for combating the disease.  In the past few decades, a phenomenal advance in the 
understanding of cell proliferation has led to a better understanding of the biology of the 
cancer cell.  This in turn has led to new approaches to the development of anticancer agents 
(Rang et al., 1999). 
 
 
1.3.1  The Biology of Cancer 
Mutation, competition, and natural selection operating within a population of somatic cells 
are the basic ingredients of cancer.   It is a disease in which individual mutant cells prosper at 
the expense of neighbouring cells (Cairns, 1975).  Cancer cells manifest, to varying degrees, 
four characteristics that distinguish them from normal cells: (1) uncontrolled proliferation, 
(2) dedifferentiation and loss of function, (3) invasiveness, and (4) metastasis (Rang et al., 
1999; Alberts et al., 1994).  An abnormal cell that proliferates uncontrollably eventually gives 
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rise to a tumour, or neoplasm, a relentlessly growing mass of abnormal cells.  Neoplastic cell 
proliferation often seems to be associated, for example, with a block in differentiation 
whereby the progeny of a stem cell are enabled to continue dividing instead of entering a 
terminal nondividing state or dying (Sachs, 1986).   
 
As long as the neoplastic cells remain clustered together in a single mass, the tumour is said 
to be benign.  A tumour is counted as a cancer only if it is malignant, that is, only if its cells 
have the ability to invade surrounding tissue.  Invasiveness usually implies an ability to break 
loose, enter the blood stream or lymphatic vessels, and form secondary tumours, or 
metastases, at other sites in the body (Robbins et al., 1989).    
 
 
1.3.2  Carcinogenesis 
Most cancers are thought to originate from a single cell that has undergone a somatic 
mutation, but the progeny of this cell must undergo further changes, probably requiring 
several additional mutations, before they become cancerous (Fialkow, 1976).  This 
phenomenon of tumour progression, which usually takes many years, reflects the operation 
of evolution by mutation and natural selection among somatic cells (Cairns, 1975; Armitage 
and Doll, 1954).  The rate of tumour progression is accelerated by mutagenic agents (tumour 
initiators, carcinogens) and by nonmutagenic agents (tumour promoters) that affect gene 
expression, stimulate cell proliferation, and alter the ecological balance of mutant and 
nonmutant cells.  Thus many factors contribute to the development of a given cancer 
(Vogelstein and Kinzler, 1993; Farber and Cameroon, 1980; Foulds, 1958). 
  
In terms of the molecular genetics of the disease, two classes of genes are critical in the 
causation of cancer, namely proto-oncogenes and tumour suppressor genes.  Proto-
oncogenes such as ras, myc, or erb B control normal growth and differentiation. However, 
they can promote malignancy when converted into active oncogenes as a result of point 
mutations, gene amplifications or chromosomal translocation, or the action of certain viruses 
(Bishop, 1991; Zur Hausen, 1991).  Tumour suppressor genes have the ability to suppress 
malignant tumours.  Loss-of-function mutations of tumour suppressor genes such as p53 
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result in uncontrolled division of cells containing abnormal DNA.  p53 mutations are found 
in 50-55% of all human cancers (Hollstein et al., 1994).    
 
 
1.3.3 The Prevalence of Various Cancers  
In South Africa, the minimal lifetime risk (LR) (excluding basal and squamous cell skin 
cancers) between 0-74 years of age of developing a cancer in males was 1 in 6 and in females 
1 in 7.  Adjusting for underreporting (i.e., those cancers diagnosed without histological 
confirmation) increases the LR to about 1 in 4.  The four different population groups, 
(White, Black, Coloured and Asian), show very different incidence rates.  Furthermore, the 
process of urbanization exposes millions of previously rural inhabitants to a growing risk for 
the so-called Western cancers such as lung, colon, breast, and prostate cancer.   
 
 
Table 1.3 Annual Cancer Incidences per 100 000 in South Africa and the USA.   
 
Cancer Type RSA 
Whites                 Blacks 
USA 
        Whites                  Blacks 
Oesophageal 5 25 4 17 
Breast 64 13 75 64 
Prostate 43 13 42 72 
Cervical 9 40 9 19 
Colon 23 3 31 32 
Taken from Sitas et al. (1998).       
 
When the incidence rates of a number of major cancers in the white and black population 
groups of South Africa and the United States are compared, very important differences are 
found (Table 1.3) (Sitas et al., 1998).  This comparison raises important questions concerning 
the higher incidence rate of oesophageal and cervical cancer in black population groups. On 
the other hand colon, breast and prostate cancers are more common in all the groups, except 
the population of black South Africans.  The combination of environmental, socio-
economic and ethnological factors creates many opportunities to study the aetiology of 
different cancers of national importance and devise applicable interventions to prevent these 
cancers (Sitas et al., 1998).   
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1.3.4  Chemotherapy 
There are three main approaches to treating established cancer, namely surgical excision, 
radiotherapy (irradiation), and chemotherapy.  The role of each of these depends on the type 
of tumour and the stage of development (Rang et al., 1999).  Cytotoxic chemotherapy is the 
treatment of neoplastic conditions with chemical substances (anticancer drugs), and is the 
main method of treatment for some cancers.  Effective cures using anticancer drugs, alone 
or in combination with other treatments, have been devised for some formerly highly lethal 
cancers (notably Hodgkin’s lymphoma, testicular cancer, choriosarcoma, and some 
leukemias) (Malpas, 1991).  The main anticancer drugs can be divided into the following 
general categories (Rang et al., 1999): 
 
 (1) Alkylating agents  
      This group contains drugs such as cyclophosphamide, nitrogen mustard,    
                 phenylalanine mustard, chlorambucil, etc.  They act by forming covalent  
                 bonds with DNA thus preventing its replication.  
 
(2) Antimetabolites 
     Included in this group are 5-fluorouracil, methotrexate, 6-mercaptopurine, etc.       
     These block or subvert one or more of the metabolic pathways involved in DNA    
     synthesis. 
 
 (3) Antitumour antibiotics    
      These drugs were originally investigated for their antimicrobial potential,  
                 and include doxorubicin, actinomycin D, verticillin A, etc.  These may intercalate          
                 in DNA producing strand breaks, or inhibit RNA synthesis. 
 
(4) Plant derivatives  
                 This group comprises vinca alkaloids (vincristine), taxanes, camptothecins, etc.    
                 Most of these specifically affect microtubule function and hence the formation of   
                 the mitotic spindle.  
 
(5) Hormones   
     The most important here are steroids, namely glucocorticoids, oestrogens and    
     androgens.  Tumours derived from hormone-sensitive tissues can be inhibited by   
     hormones with opposing actions, by hormone antagonists or by agents that   
     inhibit the synthesis of the relevant hormones. 
 
(6) Miscellaneous agents 
     This is a very mixed group of agents that do not fit into the above categories.      
     One example is hydroxyurea, a urea analogue that inhibits ribonucleotide       
     reductase and thus interferes with deoxyribonucleotide production.   
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Much effort in cancer research has been devoted to the search for ways to cure the disease 
by killing cancer cells while sparing their normal neighbours.  A rational approach to this 
problem requires an understanding of the properties that enable cancer cells to evolve, 
multiply, and spread, as well as an understanding of the mechanisms of cellular 
differentiation and cell death.  
 
 
1.3.5  Anticancer Drugs and Apoptosis 
With the discovery that distinct cell death pathways exist in biology, and that certain of these 
are evolutionarily selected and highly efficient, came a plethora of publications connecting 
such pathways to the pathophysiology of cancer.  Thus, the biology of cancer has expanded 
to incorporate not only alterations that cause uncontrolled cell growth, but also those that 
lead to inefficient cell death (Sellers and Fisher, 1999).  Traditionally, oncologists have 
focused primarily on cell proliferation.  However, apoptosis (a distinctive form of 
programmed cell death) has increasingly attracted their attention (Kerr et al., 1994).   
 
More than 30 years ago it was suggested that apoptosis may account for much of the 
spontaneous cell loss known to occur in many tumours (Kerr et al., 1972; Kerr and Searle, 
1972), and it has been clear for some time that the extent of apoptosis is enhanced in 
tumours by well-established treatment modalities, such as irradiation (Macklis et al., 1992; 
Stephens et al., 1991), and cytotoxic chemotherapy (Cotter et al., 1992; Barry et al., 1990; 
Dyson et al., 1986).  Moreover, several independent studies have provided evidence to 
demonstrate that most anticancer drugs kill tumour cells in vitro and in vivo by initiating 
apoptosis  (Huschtscha et al., 1996; Havrilesky et al., 1995; Shinomiya et al., 1994; Walker et 
al., 1991; Kaufmann, 1989) (Table 1.4).  These studies have provided significant insight into 
the mechanisms involved in cell death in general and tumour cell death more specifically.  
Such insight may allow the identification of novel targets and the development of more 
specific chemotherapeutic agents that are designed to initiate apoptosis specifically (Hannun, 
1997).   
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Table 1.4  Cancer therapy and apoptosis. 
 
 
        Some Agents Associated With Apoptosis        Cancer Types Susceptible to Apoptosis          
 
Etoposide   Camptothecin    Lymphoma 
Dexamethasone  Hydroxyurea    Leukemia 
Vincristine  5-Azacytidine    Breast carcinoma 
Cis-Platinum  Nitrogen mustard    Ovarian carcinoma 
Cyclophosphamide Methotrexate    Colon carcinoma 
Adriamycin  Chlorambucil    Prostate cancer 
Paclitaxel  Bleomycin    Miscellaneous 
5’-Flourouracil  Actinomycin D    Adenocarcinomas 
5’-Flouro-deoxyuridine Melphalan    Seminoma 
 
Taken from Hannun (1997). 
 
 
 
1.4  APOPTOSIS 
 
1.4.1 Definitions and Features of Apoptosis  
Programmed cell death (PCD) is essential for the development and maintenance of 
multicellular organisms.  PCD plays a central role in embryogenesis and normal adult tissue 
homeostasis by regulating the balance between cell death and cell proliferation.  It is also 
important for eliminating cells that are potentially harmful to the body, such as cancerous 
cells and cells harbouring viruses (Kass and Jones, 2000).  Many eukaryotic cells that die and 
are removed in a programmed way undergo an astonishingly stereotypical series of 
biochemical and morphological changes.  The most defining features of this PCD are 
chromatin condensation, the display of phagocytosis markers on the cell surface, and the 
activation of a family of proteases called caspases that are responsible for the systematic 
breakdown of the cell, culminating in “cellular suicide” (Hengartner, 2000; Kerr et al., 1972).  
The underlying death process has been called apoptosis to distinguish it clearly from other 
cell death programmes (Leist and Jäättelä, 2001). 
 
Apoptosis is fundamentally different from necrosis, which is viewed as a non-physiological 
mode of cell death, so-called accidental cell death (Kerr et al., 1972).  The contrasting 
features of apoptosis and necrosis are depicted in Figure 1.4.  The earliest recognized 
morphological changes in apoptosis are condensation and segregation of the nuclear 
chromatin, with the formation of sharply delineated, finely granular masses that become 
marginalized against the nuclear envelope.  Condensation of the cytoplasm (cell shrinkage) 
 29
and detachment from neighbouring cells are also characteristic of apoptotic cells.  
Progression of the condensation is accompanied by convolution of the nuclear and cell 
outlines, followed by breaking up of the nucleus into discrete fragments.   The nuclear 
fragments, together with constituents of the cytoplasm (including intact organelles), are then 
packaged and enveloped by fragments of the plasma membrane.  These structures, called 
“apoptotic bodies”, are then shed from the dying cell.  When apoptosis occurs in vivo, 
apoptotic bodies are phagocytosed by neighbouring cells, without triggering an inflammatory 
reaction in the tissue (Darzynkiewicz et al., 1997; Majno and Joris, 1995; Arends and Wyllie, 
1991; Wyllie et al., 1980; Kerr et al., 1972).     
 
In necrosis, the dying cell swells rather than condenses, and substantial damage to 
intracellular organelles and the plasma membrane are observed.  Nuclear chromatin shows 
patchy areas of condensation (not as defined as in apoptosis), and the nucleus undergoes 
slow dissolution (karyolysis).    The mitochondria swell, followed by rupturing of the plasma 
membrane and the release of cytoplasmic constituents, which include proteolytic enzymes 
(Majno and Joris, 1995).  Necrosis triggers an inflammatory reaction in the tissue and often 
results in scar formation (Darzynkiewicz et al., 1997).  
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Figure 1.4 Diagram illustrating the sequence of ultrastructural changes in apoptosis (2-6) and necrosis (7 and 8).  
Early apoptosis is characterized by condensation and margination of nuclear chromatin, condensation  of 
cytoplasm, and convolution of nuclear and cell outlines. (3) At a later stage, the nucleus fragments, and 
protuberances that form on the cell surface separate to produce apoptotic bodies, which (4) are phagocytosed 
by nearby cells and (5 and 6) degraded within lysosomes. (7) The development of necrosis is associated with 
irregular clumping of chromatin, marked swelling of organelles and focal disruption of membranes. (8) 
Membranes subsequently disintegrate, but the cell usually retains its overall shape until removed by 
mononuclear phagocytes.  Taken from Kerr et al. (1994). 
 
 
 
 
1.4.2 Biochemical Alterations and Signal Transduction in Apoptosis 
Apoptosis is a highly regulated process that can be induced by various stimuli, and 
stimulated or inhibited at different stages (Figure 1.5).  Apoptosis can be induced by specific 
ligand-receptor interactions.  These include tumour necrosis factor-α (TNF-α) and its p55-
receptor (TNF-R1), Fas-ligand and its Fas-receptor (Fesus, 1993).  Activation of these 
receptors leads to the formation of a signalling complex that subsequently activates a family 
of so-called initiator caspases, for example, caspase-8 (Fraser and Evan, 1996).  Other stimuli 
that can trigger induction of apoptosis include drugs and irradiation that cause damage to 
DNA, drugs that cause damage to microtubules, cytotoxic T cells, and growth factor 
withdrawal (Au et al., 1997).  Initiator caspases are responsible for the first proteolytic events 
in the apoptosis cascade, for example, the cleavage of cytoskeletal and related proteins such 
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as vimentin (van Engeland et al., 1997), actin (Kayalar et al., 1996), and fodrin (a membrane-
associated cytoskeletal protein; Martin et al., 1995).  Cleavage of translocase (flippase) and/or 
activation of scramblase (floppase) leads to a subsequent translocation of phosphatidylserine 
(PS) from the inner to the outer leaflet of the plasma membrane.  This is known to be a very 
early event during the initial stages of apoptosis (Verhoven et al., 1995).  Externalization of 
PS is used by cells as a signal for events such as the attraction of macrophages and associated 
phagocytosis (Fadok et al., 1992).   
 
Initiator caspases are positioned at the top of the caspase hierarchy (Cohen, 1997).  
Subsequently they cleave and thus activate a second subpopulation of caspases known as the 
execution caspases (Mignotte and Vayssiere, 1998).  The activation of execution caspases is 
tightly regulated by the Bcl-2 family of mitochondrial proteins. The various members of this 
family promote (Bad, Bak, Bid, Bax, Bcl-xS, Bik, Hrk) or inhibit (A1, Bcl-2, Bcl-w, Bcl-xL, 
Bfl-1, Brag-1, Mcl-1, NR13) cleavage of execution caspases (Mignotte and Vayssiere, 1998; 
Renvoize et al., 1997; Hockenberry et al., 1990).   Irreversible progression of apoptosis by 
activated execution caspases (e.g., caspase-3) requires that these enzymes remain active for a 
critical minimum period of time.  This varies from minutes to hours depending on the size, 
type and functional state of the cell (Marks et al., 1998).   
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Figure 1.5 The apoptosis cascade can be divided into three sets of sequential stages.  Initiation stages include 
the induction of the cascade, for example by ligand-receptor interactions leading to first proteolytic events 
executed by initiator caspases.  Execution stages start with the activation of the execution caspases. Their 
activation is called the “point of no return” as once activated, these proteases degrade a variety of proteins 
resulting in irreversible damage of the cell.  Finally apoptotic death is the result of a very complex cascade of 
events that leads to the collapse of the nucleus and the cell itself.  Even in this final stage the cell does not 
release intracellular components, thus avoiding inflammatory reactions.  Taken from Huppertz et al. (1999). 
 
 
Once activated, the execution caspases, either directly or by means of other proteases, cleave 
a broad array of proteins critical for cell survival.  The latter include intermediate filament 
proteins (such as cytokeratin 18; Caulin et al., 1997), nuclear envelope proteins (such as 
lamins A and B; Greidinger et al., 1996), proteins involved in DNA repair and maintenance 
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[such as poly-(ADP-ribose) polymerase (PARP); Nicholson et al., 1995), enzymes involved in 
relaxation of the DNA helix and separation of chromosomes during mitosis (topoisomerase 
IIα; Nakajima et al., 1996).  There is considerable evidence that several of the caspases are 
responsible for many, if not all, of the features of apoptosis.  The cleavage of cytoskeletal 
elements such as fodrin, keratins and actin by caspases appears to contribute to the changes 
in cell morphology.  Likewise, the proteolysis of nuclear lamins has been linked to chromatin 
condensation (Kass and Jones, 2000).  Execution caspases activate DFF (DNA 
fragmentation factor) and other endonucleases resulting in specific fragmentation of DNA 
(Liu et al., 1997).  In summary, the final apoptotic events comprise; down-regulation of 
transcription, fragmentation and condensation of DNA, alteration of nuclear and cellular 
shape, and finally formation of apoptotic bodies (Kerr et al., 1995).  
 
It has been well established that there are at least two pathways that lead to apoptotic cell 
death, both of which converge on the activation of the execution caspases -3, -6 and -7.  
One pathway involves the so-called death receptors (Fas, TNFα) with caspase-8 as the most 
apical caspase.  The other pathway is triggered by a variety of cytotoxic agents, leading to the 
release of cytochrome c from mitochondria, and the activation of caspase-9, which is the 
most apical caspase in this pathway.  (Kroemer and Reed, 2000; Slee et al., 1999; Sun et al., 
1999; Stennicke and Salvesen, 1998).  For example, Sun et al. (1999) demonstrated that 
distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis 
(Figure 1.6).   
 
While a number of initial studies suggested that apoptosis triggered by cancer therapy 
involves activation of the CD95 receptor/ligand system, compelling evidence subsequently 
indicated that the majority of cytotoxic drugs initiate cell death by triggering the cytochrome-
c/Apaf-1/caspase-9-dependent pathway through the mitochondria (Debatin, 2004).  This  
pathway is executed via the caspase-9 activator complex referred to as the apoptosome 
(Stennicke and Salvesen, 1998).  The apoptosome consists of Apaf-1 (a scaffolding protein), 
cytochrome c, dATP and caspase-9.  The binding of Apaf-1 results in the autoactivation of 
procaspase-9.  Active caspase-9 then cleaves execution caspases such as caspase-3 (Kroemer 
and Reed, 2000).   
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Figure 1.6 Scheme for receptor-mediated and chemical-induced apoptosis.  Triggering of death receptors, such 
as Fas (CD95) or TNF, results in activation of caspase-8. Caspase-8 may directly activate execution caspases, -3 
and -7.  Alternatively caspase-8 can act indirectly by cleaving cytosolic factors, such as Bid, leading to the 
release of cytochrome c and activation of caspase-9 with subsequent activation of the execution caspases.  In 
chemical-induced apoptosis, undefined signals lead to perturbation of mitochondria (Mit) and release of 
cytochrome c and then activation of caspases.  Taken from Sun et al. (1999).  
 
  
 
 
1.4.3  The Caspases and Apoptosis 
The elucidation of the role of caspases in apoptotic execution began in the early 1990s with 
genetic and biochemical studies of apoptotic cell death in the nematode C. elegans.  These 
studies revealed that apoptosis in C. elegans was dependent on an intracellular protease 
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bearing considerable homology to the human interleukin-1β-converting enzyme (ICE) 
(Alnemri et al., 1996).  At least 11 caspases, related to ICE, have been identified as essential 
components of many apoptotic signalling pathways (Wang et al., 1994; Muzio et al., 1996).  
The term caspase is based on a common nomenclature system adopted by investigators in 
the field; "c" reflects a cysteine protease mechanism, and "aspase" refers to the ability of 
these proteases to cleave a protein following an aspartic acid residue (Wilson et al., 1994).  
Caspase designation for 11 human members of this family, their structural organization, 
deduced biological function, and phylogenetic relationship are depicted in Figure 1.7.  Many 
of the caspase enzymes contain a conserved sequence, QAC(R/Q)G, required for the 
catalytic activity of these enzymes (Wilson et al., 1994).   
 
Among the various members of the caspase family, caspase-3 exhibits the highest similarity 
to CED-3, the prototype of cell death genes in the nematode, in both sequence homology 
and substrate specificity (Nicholson et al., 1995).  The active form of caspase-3 is capable of 
cleaving PARP (Lazebnik et al., 1994).  PARP (Mr 113 kDa) is an enzyme that appears to be 
involved in DNA repair, genome surveillance, and integrity (Casciola-Rosen et al., 1994).  
Proteolytic cleavage of PARP prevents the catalytic domain of PARP from being recruited 
to sites of DNA damage and presumably disables PARP from coordinating subsequent 
repair and genome maintenance.  Nicholson et al. (1995) have demonstrated that caspase-3-
mediated cleavage of PARP occurs at the onset of apoptosis, and inhibition of PARP 
cleavage attenuates apoptosis in vitro.  Although most caspases are able to cleave PARP, 
caspase-3 and caspase-7 have a much higher affinity for PARP and are considered to be 
essential for the execution of apoptosis (Germain et al., 1999).  The caspase-dependent 
cleavage of PARP to Mr 89 and 24 kDa signature fragments has become a hallmark for 
apoptosis in different types of cells responding to a wide range of apoptotic agents (Boucher 
et al., 2001).  
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Figure 1.7 Structural representation and organization of human caspases, as well as their functional and 
phylogenic relationships.  Prodomains and large and small subunits are each shown in different colours with 
markings to indicate the position of the cleavage sites.  (Left) Deduced biological functions of these caspases. 
(Right) The phylogenic relationship among caspases.  Taken from Srinivasula et al. (2001). 
 
 
 
 
1.4.4  Non-caspase Proteases in Apoptosis 
The unexpected ability of certain cells to survive the activation of pro-apoptotic caspases 
demonstrates a remarkable plasticity of the cellular death programme, and does not support 
the idea that caspases alone are sufficient for the induction of mammalian PCD (Leist and 
Jäättelä, 2001).  Many non-caspase proteases can cleave at least some of the classical caspase 
substrates, indicating that they might also mimic the cellular effects of caspases (Waterhouse 
et al., 1998; Johnson, 2000).  While the importance of caspases in apoptosis is clearly 
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established, recent studies have indicated that several other types of proteases may play a role 
in the execution process (Johnson, 2000).  Accordingly, evidence is emerging for the ability 
of other proteases to induce apoptosis-like PCD independent of caspase activation.  Specific 
examples include the roles of cathepsins D and B in camptothecin-induced death of liver 
cancer cells (Roberts et al., 1999); and of calpains implicated in the induction of apoptosis in 
MCF-7 breast cancer cells (Pink et al., 2000).  Calpain activation has been detected in 
response to a variety of apoptotic stimuli, in a variety of cell types (Johnson, 2000).  The 
existence of alternative and caspase-independent cell death pathways may provide new 
options for killing tumour cells in the future.  Here, calpains and cathepsins are discussed as 
two groups of non-caspase proteases that have been clearly linked to various modes of 
apoptotic cell death. 
 
1.4.4.1  Calpains 
Calpains are activated by various stimuli that increase the [Ca2+]i, and they can participate in 
PCD signalling upstream or downstream of caspases (Wang, 2000).  Calpain activation has 
been assessed using several different assays including, Western blotting to detect calpain 
autolysis or cleavage of known calpain substrates, and in vitro and whole cell assays to detect 
cleavage of the fluorogenic calpain substrate N-s-LLVY-AMC.  Using these and a few less 
common assays, calpain activation has been detected in response to a variety of apoptotic 
stimuli, in a variety of different cell types (Johnson, 2000).  Furthermore, calpains can 
mediate apoptosis-like PCD (see glossary) in the absence of caspase activation.  For example, 
EB1089/seocalcitol, a vitamin D analogue currently in phase III clinical trials for the 
treatment of cancer, induces Ca2+- and calpain-dependent apoptosis-like PCD in breast 
cancer cells without triggering detectable caspase activation (Mathiasen et al., 1999). 
 
1.4.4.2  Cathepsins  
So far, cysteine cathepsins B and L and aspartate cathepsin D have been most clearly linked 
to PCD (Roberts et al., 1999).  Cathepsins participate in both caspase-dependent and 
caspase-independent PCD induced by a variety of stimuli, including death receptors, 
camptothecin, bile salts, oxidants and retinoids.  In all of these models, cathepsins 
translocate from lysosomes to the cytosol and/or nucleus before the appearance of gross 
morphological changes indicative of PCD (Mathiasen and Jäättelä, 2002).  In cell culture, bile 
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salt-induced apoptosis was found to be markedly inhibited by CA-074-Me, a specific 
inhibitor of cathepsin B, and pepstatin A, an inhibitor of cathepsin D.  Antsense-mediated 
down-regulation of cathepsin B also markedly inhibited hepatocyte apoptosis following 
treatment with bile salts (Roberts et al., 1999). 
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CHAPTER 2: INTRODUCTION TO THE PRESENT STUDY 
 
 
The biological diversity of CDPs is exemplified by their ubiquitous nature, interesting 
physicochemical properties and the wide range of biological processes affected by this 
unique group of compounds.  Furthermore, the presence of cyclic constraints presents 
important physiological advantages for CDPs.  They are more resistant to enzymatic 
degradation, thus having greater stability compared to their linear counterparts.  They are 
able to cross various physiological barriers, and their limited conformational freedom allows 
attainment of a bioactive conformation that may give rise to improved receptor site 
selectivity and pharmacological specificity (Smith et al., 1992; Mc Dowell and Gadek, 1992). 
 
Proline-based CDPs are of particular interest because of their prevalence in a variety of 
processed foods and beverages (Dansi et al., 1970; Rizzi, 1989; Roudot-Algaron et al., 1993; 
Eriksen and Fagerson, 1980; Takahashi et al., 1974; Kawai et al., 1991; Gautschi and Schmid, 
1997; Ginz & Engelhardt, 2000), and their interesting biological activity, particularly their 
implication in the induction of differentiation in colon cancer cells (Graz et al., 2000).  
Although some DKP-type metabolites have been isolated from various microorganisms as 
mycotoxins or antitumour agents, the antitumour potential of CDPs remains largely 
unexplored (Kanoh et al., 1999). 
 
In the present study it is proposed that selected proline-based CDPs have the potential to 
inhibit cancer cell growth and induce apoptotic programmed cell death in cancer cells.  This 
raises interest in terms of (1) the implications for consumption of processed foods 
containing proline-based CDPs, and (2) the possible clinical usefulness of these compounds 
and other CDPs in the context of anticancer therapy.  The objectives of the present study 
were to explore the potential of proline-based CDPs to inhibit the growth of cancer cells in 
vitro and to investigate whether this potential could be linked to the induction of apoptosis as 
a favourable mechanism of effecting cancer cell death.  To achieve these objectives, the 
experimental design of the present study included the following aspects:  
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(1) The selection of cyclic dipeptides 
(2) Assays of cell growth and viability 
(3) Detection of apoptosis. 
 
 
2.1  SELECTION OF CYCLIC DIPEPTIDES 
 
The chemical structures of the seven proline-based cyclic dipeptides used in this study are 
shown in Figure 2.1.  Cyclo(Gly-Pro), cyclo(Pro-Pro) and cyclo(Leu-Pro) have amino acids 
with neutral side chains.  The aromatic side chains in cyclo(Phe-Pro) and cyclo(Tyr-Pro) 
render these peptides highly hydrophobic.  The hydroxyl group of tyrosine makes cyclo(Tyr-
Pro) less hydrophobic than cyclo(Phe-Pro).  Cyclo(Thr-Pro) is a hydrophilic peptide owing 
to the aliphatic hydroxyl group of threonine.  The imidazole ring of cyclo(His-Pro) can be 
uncharged or positively charged, depending on its local environment.  Cyclo(Gly-Pro), 
cyclo(Pro-Pro), cyclo(Leu-Pro), cyclo(Thr-Pro) and cyclo(His-Pro) were purchased from 
Bachem (Germany).  Cyclo(Phe-Pro) and cyclo(Tyr-Pro) were synthesized from the 
corresponding linear dipeptides.  The synthesis and structural elucidation of cyclo(Phe-Pro) 
and cyclo(Tyr-Pro) are discussed in detail in Chapter 3.   
 
The initial proposal for this study included the choice of cyclic dipeptides with very polar 
amino acid side chains, such as cyclo(Asp-Pro) (acidic) and cyclo(Lys-Pro) (basic).  However, 
these peptides were not available from a commercial supplier, and attempts to synthesize 
cyclo(Asp-Pro) and cyclo(Lys-Pro) in our laboratory proved to be very difficult because of 
undesired side reactions caused by the carboxyl group in the side chain of aspartate and the 
ε-amino group of the lysine side chain.  Removal of the protecting groups, as part of the 
peptide synthesis, resulted in a low percentage yield for both CDPs.  Cyclo(Asp-Pro) and 
cyclo(Lys-Pro) were thus excluded from the selection of CDPs in the present study.       
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Figure 2.1 Chemical structures of the seven proline-based CDPs used in the present study (pH 7.0). 
 
 
 
2.2  ASSAYS OF CELL GROWTH AND VIABILITY 
The initial screening of potential anticancer compounds is commonly performed in vitro.  
Most studies concentrate on determining the effects of drugs directly at the cellular level 
(Freshney, 2000).  There are a large number of established human cancer cell lines that 
present convenient in vitro cell models to study drug-induced effects such as cell growth 
inhibition or cytotoxicity.  For example, the National Cancer Institute of the USA has 
implemented an anticancer drug-screening program in which each compound is tested 
against multiple cell lines representing a variety of tumour types (Monks et al., 1991). 
N
N
N
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N
H
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In the present study, the effects of cyclic dipeptides on cell growth and viability were tested 
against four human cancer cell lines, namely HT-29, MCF-7, HeLa, and WHCO3.  These 
cell lines are representative of colon, breast, cervical, and oesophageal cancer, respectively. 
The cancers listed here are among the top five cancers in South Africa and the USA, in 
terms of incidence per one hundred thousand (100 000) (Sitas et al., 1998).   
 
The cellular response to the CDPs was determined by measuring (1) the change in cell mass 
(total protein) by using the sulforhodamine B (SRB) assay (Skehan et al., 1990), and (2) the 
fraction of metabolically active (living) cells using the MTT assay (Alley et al., 1988).  The 
SRB assay does not distinguish between live and dead cells, and was therefore used as an 
initial screening assay.  The MTT assay, incorporating a longer drug incubation time, was 
used to confirm the SRB assay results for those CDPs that exhibited the highest growth 
inhibition.  Further details of both assays are discussed in Chapter 4. 
 
 
2.3  DETECTION OF APOPTOSIS 
As discussed in Chapter 1 (section 1.3.5), most anticancer drugs that are in current clinical 
use kill their target cells by apoptosis (Huschtscha et al., 1996; Havrilesky et al., 1995; 
Shinomiya et al., 1994; Walker et al., 1991; Kaufmann, 1989).  In the present study, the 
detection of apoptosis was investigated using the HT-29 colon cancer cell line, which is a 
well-studied model of apoptosis in an adherent cell line (Desjardins & MacManus, 1995). 
 
Morphology remains the definite criterion for apoptosis and should always be used to 
confirm any biochemical evidence of apoptosis (Kass and Jones, 2000).  Both morphological 
and biochemical methods were used to investigate the induction of apoptosis in this study.  
Phase-contrast microscopy was used to study morphological features of apoptosis, including 
cell shrinkage and detachment from neighbouring cells, whereas fluorescence microscopy 
was used to study chromatin condensation and nuclear fragmentation.  Biochemical methods 
of detection included (1) annexin V binding to indicate phosphatidylserine externalization, 
(2) western blot analysis for detection of PARP cleavage, including inhibitor studies, and (3) 
assaying for caspase-3 activity using a synthetic substrate.  All methods used for the 
detection of apoptosis are discussed in detail in Chapter 5.      
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CHAPTER 3: SYNTHESIS AND STRUCTURAL 
ELUCIDATION OF CYCLO(PHE-PRO) AND CYCLO(TYR-
PRO) 
 
 
3.1  INTRODUCTION 
Cyclo(Gly-Gly) was the first cyclic dipeptide to be synthesized and elucidated and since then 
a variety of cyclic dipeptide derivatives have been synthesized by various methods (Sammes, 
1975).  Cyclic dipeptides were initially prepared by the action of ammonia on the free 
dipeptide esters, liberated from the corresponding amine salts. The long duration of 
exposure to ammonia led to extensive racemization when employing optically pure dipeptide 
precursors (Blaha, 1969).  Alternate methods have since been developed to minimize the 
racemization, thereby improving yield.   
 
Two current and prominent methods of cyclic dipeptide synthesis include cyclization in 
neutral solvents (Kopple, 1972; Nitecki et al., 1967), and phenol-induced cyclization of 
unprotected dipeptides (Kopple and Ghazarian, 1968).  Reports of consistent high yields, 
formation of sterically pure cyclic products and commercial availability of free dipeptides, 
suggest that the procedure utilizing phenol for cyclization is the method of choice.  A 
schematic representation of phenol-induced cyclization of Gly-Gly to cyclo(Gly-Gly) is 
shown in Figure 3.1.   
 
 
     
 
Figure 3.1  Phenol cyclization of cyclo(Gly-Gly) from the linear precursor H-Gly-Gly-OH.  Taken from Grant 
(2002).  
 
 
 44
Cyclo(Phe-Pro) and cyclo(Tyr-Pro) were synthesized by phenol-induced cyclization of the 
corresponding linear precursors according to Kopple and Ghazarian (1968).  The synthetic 
products of both cyclic dipeptides were tested for phenol contamination by using high 
performance liquid chromatography (HPLC).  This test was conducted to ensure that the 
cyclic dipeptides were free of trace amounts of phenol that may interfere with biological 
assays or have a cytotoxic effect on the cell cultures.   
 
Characterization of cyclo(Phe-Pro) and cyclo(Tyr-Pro) included the analysis of their 
physicochemical properties by thin layer chromatography (TLC), differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA).  The structural detail of each 
cyclic dipeptide was confirmed by nuclear magnetic resonance spectroscopy (NMR), mass 
spectrometry (MS), and infrared (IR) spectroscopy.   The three-dimensional structures of 
cyclo(Phe-Pro) and cyclo(Tyr-Pro) were compared by examining structural overlays of the 
two cyclic dipeptides using HyperChem® software.  
 
The format of this chapter does not include separate sections for Methods and Results. 
Instead, the principle and methodology of each analytical technique are described briefly, 
followed by a presentation and discussion of the corresponding results.  
 
3.2  SYNTHESIS OF CYCLO(PHE-PRO) AND CYCLO(TYR-PRO) 
 
3.2.1  Phenol-induced Cyclization of Linear Precursors 
The linear precursors, namely H-Phe-Pro-OH (1 g) and H-Tyr-Pro-OH (1 g) (Bachem, 
Germany) were mixed with 10 g of phenol, respectively, and refluxed in an oil bath kept at 
140-150°C with constant magnetic stirring.  The dipeptides dissolved in the molten phenol 
within a few minutes and the reaction was continued for 90 min.  The phenol was removed 
by sublimation under vacuum at room temperature and the precipitate was washed 
thoroughly with several portions of ether and dried, yielding the crude products cyclo(Phe-
Pro) and cyclo(Tyr-Pro) respectively.  The residues were crystallized from ethanol and water, 
with yields of 89 and 93 %, respectively. 
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The test for the presence of phenol was performed on a HPLC system consisting of a dual 
pump Beckman (System Gold) 128 Solvent Model, a Waters (Millipore) TSK ODS 120T 
column (4.6 x 250 mm), acetonitrile:water (40:60) as mobile phase, and a Beckman 168 diode 
array detector.  The HPLC system was operated by using System Gold software.  The 
absorbance of phenol was measured at 254 nm.  The CDPs were also detectable at 254 nm.  
The phenol calibration curve and representative chromatograms are included in Appendix A 
(Figures A1 to A4).  Results show that no phenol was present in either cyclo(Phe-Pro) or 
cyclo(Tyr-Pro). 
 
 
3.3  PHYSICOCHEMICAL CHARACTERIZATION 
 
3.3.1 Thin Layer Chromatography  
TLC of cyclo(Phe-Pro) and cyclo(Tyr-Pro) was performed on silica-gel plates (Silica gel 60 
F254, Merck, Germany) using chloroform-methanol-acetic acid (C-M-A) (14:2:1) or 
chloroform-methanol (C-M) (7:3) as mobile phase.  The corresponding Rf values were 0.722 
(C-M-A) and 0.713 (C-M) for cyclo(Phe-Pro), and 0.589 (C-M-A) and 0.621 (C-M) for 
cyclo(Tyr-Pro). 
 
 
3.3.2 Thermal Analysis 
The physical properties of cyclo(Phe-Pro) and cyclo(Tyr-Pro) were determined  by DSC and 
TGA.  DSC involves the measurement of changes in heat capacity of a material as a function 
of temperature. TGA involves the measurement of weight changes of a material as a 
function of temperature.   
 
DSC and TGA were performed on a TA Instruments 10 DSC and TA Instruments 2050 
TGA, respectively.  For the DSC thermograms, a mass of CDP between 3.0 to 5.0 mg was 
measured into aluminium crimp cells.  DSC curves were obtained at a heating rate of 10°C 
per minute, under a nitrogen flow of 20 ml per minute.  TGA thermograms were recorded 
by using sample sizes between 5.0 to 8.0 mg.  TGA curves were obtained by a heating rate of 
10°C per minute, under a nitrogen flow of 20 ml per minute. 
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The resultant thermograms are shown in Figure 3.2 (DSC) and Figure 3.3 (TGA) for 
cyclo(Phe-Pro), and Figure 3.4 (DSC) and Figure 3.5 (TGA) for cyclo(Tyr-Pro).  The 
thermograms revealed no significant desolvation endotherms or recrystallization exotherms 
for either of the cyclic dipeptides.  The only significant endotherm observed, for both cyclic 
dipeptides, corresponded to the respective melting points for each compound.  The 
observed melting points were 134.37°C for cyclo(Phe-Pro) and 142.81°C for cyclo(Tyr-Pro).  
TGA thermograms showed that decomposition occurred at temperatures in excess of the 
melting point of each cyclic dipeptide.  The high temperatures at which this decomposition 
was observed, suggest that the solid-state cyclic dipeptides have a high degree of thermo-
stability.  
 
 
3.3.3 Solubility  
The solubility of cyclo(Phe-Pro) and cyclo(Tyr-Pro) was tested in a few solvents that are  
compatible with biological assays.  Cyclo(Phe-Pro) was sparingly soluble (<1 mg/ml) in 
water, phosphate buffered saline (PBS), 25 mM HEPES buffer and dimethyl formamide 
(DMF). Cyclo(Tyr-Pro), which has more polar character than cyclo(Phe-Pro), was 
appreciably soluble (~1 mg/ml) in water and aqueous buffers as well as DMF.  Both cyclic 
dipeptides were completely soluble (>20 mg/ml) in dimethyl sulfoxide (DMSO).  DMSO 
was subsequently used as a solvent in all biological assays at a final concentration of 0.5%. 
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Figure 3.2  DSC thermogram of cyclo(Phe-Pro). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3  TGA thermogram of cyclo(Phe-Pro). 
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Figure 3.4  DSC thermogram of cyclo(Tyr-Pro). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
 
Figure 3.5  TGA thermogram of cyclo(Tyr-Pro).  
 
142.81°C
-0.25
0.00
0.25
0.50
H
ea
t F
lo
w
 (W
/g
)
0 50 100 150 200
Temperature (°C)
Sample: Cyclo(Tyr-Pro)
Size:   1.6480 mg
 Instrument: DSC Q100 V6.21 Build 233
Exo Up Universal V3.6C TA Instruments
0
20
40
60
80
100
W
ei
gh
t (
%
)
0 100 200 300 400 500 600
Temperature (°C)
Sample: CYCLO(TYR-PRO)
Size:   1.6530 mg
 Instrument: 2050 TGA V5.1A
Universal V3.6C TA Instruments
 49
3.4  STRUCTURAL ELUCIDATION   
 
3.4.1 Infrared Spectroscopy 
IR spectroscopy is characterised by radiation at wavelengths between 0.7 and 500 µm (14 
000 to 20 cm-1).  Absorbance of infrared light near particular frequencies is characteristic for 
specific chemical groups.  IR spectroscopy is primarily used to determine the functional 
groups present in small molecules (Sheehan, 2000).  In terms of qualitative analysis, based on 
characteristic stretching and bending motions of a molecule, IR spectroscopy allows for the 
reliable discrimination between cis and trans conformations of various bonds (Susi, 1969).   
The absorption bands listed in Table 3.1 are characteristic of the cis- and trans-amide bonds 
found in DKPs (Sammes, 1975).  
 
 
Table 3.1  Characteristic absorption bands of DKPs.  Taken from Sammes (1975). 
 
  Cis-amide         Trans-amide  
                  Description of band        absorption bands (cm-1) absorption bands (cm-1)         
 
Amide I band (CO stretch)  1670-1690    1650 
 
Amide II band   1440-1450   1550* 
(NH in-plane vibration) 
 
            Amide III (cis CONH)  1300-1350           not present 
 
NH bending       1450    1450 
 
CN stretching       1350    1350 
 
*Existence of a band at 1550 cm-1 is regarded as characteristic of the presence of a trans-amide bond (Bellamy, 
1957). 
 
 
 
The IR spectra for cyclo(Phe-Pro) and cyclo(Tyr-Pro) were recorded on a Perkin-Elmer 
1600 Fourier transform IR (FTIR) spectrophotometer using the KBr disk technique 
(Gordon and Macrae, 1987).  Samples weighing approximately 2 mg were mixed with 200 
mg of spectral grade KBr (Merck, USA) and the mixtures were ground with an agate mortar 
and pestle.  A Perkin-Elmer bench press was utilized to compress transparent disks suitable 
for IR analysis.  Spectra recorded between 400 to 4000 cm-1 were analysed for cyclo(Phe-
Pro) and cyclo(Tyr-Pro).        
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The IR spectra of cyclo(Phe-Pro) and cyclo(Tyr-Pro) are shown in Figures 3.6 and 3.7, 
respectively.  The overlay of IR spectra of cyclo(Phe-Pro) and cyclo(Tyr-Pro) is shown in 
Figure A5 (Appendix A).  The absorption bands observed for cyclo(Phe-Pro) and cyclo(Tyr-
Pro) are listed in Table 3.2.  Both cyclic dipeptides were found to be in the cis-conformation. 
 
 
Table 3.2  Absorption bands observed for cyclo(Phe-Pro) and cyclo(Tyr-Pro). 
 
             Description of band         cyclo(Phe-Pro)                             cyclo(Tyr-Pro) 
 
           Amide I band (CO stretch)            1665.0           1668.0 
 
Amide II band             1474.2          1473.3 
           (NH in-plane vibration) 
 
            Amide III (cis CONH)            1300.2                       1313.6 
 
NH bending             1442.1                     1440.0 
 
CN stretching             1339.5          1340.4 
 
          Cis- or Trans-amide bond                            cis            cis 
 
 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6  The infrared spectrum of cyclo(Phe-Pro), obtained on a 1600 FTIR Perkin-Elmer 
spectrophotometer using the KBr disk technique. 
%T 
Wavelength (cm-1) 
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Figure 3.7  The infrared spectrum of cyclo(Tyr-Pro), obtained on a 1600 FTIR Perkin-Elmer 
spectrophotometer using the KBr disk technique. 
 
 
3.4.2 Mass Spectrometry 
MS involves the high-energy ionization of molecules in order to determine a highly accurate 
mass for a particular chemical species or to fragment it into smaller pieces, and use the 
pattern of fragments (mass spectrum) observed to deduce the complete structure of the 
original molecule (Sheehan, 2000). 
 
In this study, fast atom bombardment mass spectrometry (FAB-MS) was performed on a 
VG-7070E mass spectrometer (VF, Biotech, Altrincham, UK).  DMSO-d6 was used as 
solvent and 3-nitrobenzyl alcohol as matrix.  FAB-MS is one of the most reliable ionization 
techniques for the detection of drug molecules (Henczi and Weaver, 1995).  It uses a high 
pressure of argon (Ar) gas that is placed between the sample and the ioniser.  The ionised Ar 
gas is directed at an atom beam that bombards the sample.  This high kinetic energy Ar+ 
beam exchanges charge with the solvent used to dissolve the sample, thereby ionising it.  
%T 
     Wavelength (cm-1) 
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Protons are then transferred from the solvent to the sample resulting in an observed mass of 
(m + 1) (protonated), where m is the calculated theoretical mass.      
 
In the analysis of mass spectra of simple DKPs, characteristic fragmentation patterns are 
evident. The parent ion dominates the following fragmentations: 
a)  loss of CO or CHO; 
b)  amine fragmentation (R2CH=+NH2); and  
c)  elimination of cyanuric acid (HNCO) 
(Sammes, 1975). 
 
When proline is present in some DKPs , there is a 2 mass unit shift to the left of some 
characteristic peaks (Svec and Junk, 1964).  The following ions usually indicate the existence 
of a DKP ring : m/z 114; m/z 113; and m/z 85 (Szafranek et al., 1976).    
 
 
The mass spectra for cyclo(Phe-Pro) and cyclo(Tyr-Pro) are shown in Figures 3.8 and 3.9, 
respectively.  The parent peaks for both cyclic dipeptides correspond to the exact molecular 
mass of the respective protonated molecules (Table 3.3).  The fragmentation peak at m/z = 
154 in both spectra is indicative of the DKP-pyrrolidine fragment.  The peaks at m/z = 107, 
120 and 136 represent the positive ion fragments [C7H7O]+, [C8H10N]+ and [C7H9N2O2]+, 
respectively. 
 
 
Table 3.3  The respective molecular formulae and mass observed for the protonated forms of the CDPs, as 
determined by FAB-MS. 
 
        Compound            Mol. Formula      Acc. Mass Calc (m/z)      Acc. Mass Obs. (m/z) 
 
     Cyclo(Phe-Pro)            C14H17N2O2                                       245.129003                          245.129902  
 
      Cyclo(Tyr-Pro)            C14H17N2O3                          261.123918                         261.123997  
 
(m/z) refers to the mass/charge ratio
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Figure 3.8  FAB-mass spectrum of cyclo(Phe-Pro). 
 
 
 
 
 
 
 
Figure 3.9  FAB-mass spectrum of cyclo(Tyr-Pro). 
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3.4.3 Nuclear Magnetic Resonance Spectroscopy 
NMR spectroscopy is based on the magnetic spin property of atomic nuclei.  NMR is a 
versatile analytical technique suitable for determining structural and dynamic information on 
samples ranging from amino acids and peptides to proteins of up to 30 kDa (Sheehan, 2000).   
 
All NMR spectra were acquired on a Bruker AM-400 MHz spectrophotometer with DMSO-
d6 as solvent, and tetramethylsilane (TMS) as the internal standard.  All resonances were 
reported in ppm (δ) downfield of TMS.  1H NMR (400.13 MHz), 13C NMR (100.61 MHz), 
COSY and HETCOR spectra were recorded and evaluated to assist in structural elucidation 
of cyclo(Phe-Pro) and cyclo(Tyr-Pro).  COSY spectra are homonuclear two-dimensional 
(2D) 1H-1H correlated spectra, while HETCOR refers to heteronuclear 2D 1H-13C chemical 
shift correlation.  The 2D 1H-13C HETCOR and 1H-1H COSY spectra are useful in 
confirming proton and carbon assignments as they indicate proton-carbon and proton-
proton coupling, respectively (Günther, 1995).   
 
The 13C NMR spectra of cyclo(Phe-Pro) and cyclo(Tyr-Pro) are shown in Figures 3.10 and 
3.11, respectively.  The 1H NMR spectra of both cyclic dipeptides are included in Appendix 
A (Figures A6 and A7).  The δ-values (in ppm) of cyclo(Phe-Pro) and cyclo(Tyr-Pro) are 
indicated in Tables 3.4 and 3.5, respectively.  The COSY and HETCOR spectra of 
cyclo(Phe-Pro) are shown in Figures 3.12 and 3.13, respectively.  The COSY and HETCOR 
spectra of cyclo(Tyr-Pro) are shown in Figures 3.14 and 3.15, respectively. 
 
There is a shift in the signal for the Phe-α proton in cyclo(Phe-Pro) to a lower field (4.33 
ppm) (Table 3.4) compared to the corresponding resonance in cyclo(Tyr-Pro) (4.24 ppm) 
(Table 3.5).  The observed chemical shifts of the 1H-NMR spectra for both cyclic dipeptides 
indicate that the γ-protons of Pro exist as chemically equivalent proton groups (1.72 ppm) 
(Tables 3.4 and 3.5).  The two Pro-δ protons of cyclo(Phe-Pro) differ by 0.13 ppm (3.37; 
3.24 ppm).  The observed chemical shift for cyclo(Tyr-Pro) (3.26 ppm) indicates that the δ-
protons exist as chemically equivalent proton groups. 
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The two Pro-β protons of cyclo(Phe-Pro) differ by 0.58 ppm (1.41; 199 ppm) (Table 3.4), 
compared to that of the corresponding protons of cyclo(Tyr-Pro), which differ by 0.57 ppm 
(1.95; 1.38 ppm) (Table 3.5).  The two Phe-β protons of cyclo(Phe-Pro) (3.03 ppm) (Table 
3.4) shifted downfield by 0.12 ppm when compared to the corresponding resonance of 
cyclo(Tyr-Pro) (2.91 ppm) (Table 3.5).  Equal couplings may be expected for a folded 
conformation, whereas one large and one small coupling would represent an unfolded 
conformation (Pachler, 1964).  The 1H-NMR studies of cyclo(Phe-Pro) and cyclo(Tyr-Pro) 
indicate folded conformations for the aromatic side chains with vicinal coupling constants of 
Jv = 5.2 Hz, 5.0 Hz; and Jv = 9.6 Hz, 9.6 Hz, respectively.  
 
The Tyr-β carbon of cyclo(Tyr-Pro) (34.61 ppm) (Table 3.5) is shifted upfield by 0.69 ppm 
when compared to the corresponding resonance in cyclo(Phe-Pro) (35.3 ppm) (Table 3.4).  
The Phe-α carbon of cyclo(Phe-Pro) (55.7 ppm) (Table 3.4) is shifted upfield by 0.19 ppm 
when compared to the Tyr-α carbon signal (55.89 ppm) (Table 3.5). 
 
 
Table 3.4  1H NMR (400.13 MHz)  and 13C NMR (100.61 MHz) data for cyclo(Phe-Pro). 
  
    Proton            δ (ppm)               Carbon Atom           δ (ppm) 
         
    Pro – β    1.41             Pro – γ               21.8 
    Pro – γ   1.72             Pro – β                 27.7 
    Pro – β    1.99             Phe – β                             35.3 
    Phe – β    3.03             Pro – δ               44.5 
    Pro – δ    3.24             Phe – α               55.7 
    Pro – δ    3.37             Pro – α               58.3 
    Pro – α    4.05             Phe – Ar             126.2 
    Phe – α   4.33             Phe – Ar             127.9 
    Phe – Ar  7.17             Phe – Ar             129.7 
    Phe – Ar  7.22             Phe – Ar             137.2 
    Phe – NH  7.93             Pro – C=O             165.0 
                 Pro – C=O                          169.0 
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Table 3.5  1H NMR (400.13 MHz)  and 13C NMR (100.61 MHz) data for cyclo(Tyr-Pro). 
 
    Proton             δ (ppm)                                   Carbon Atom            δ (ppm) 
 
    Pro – β    1.38                                              Pro – γ               21.72 
    Pro – γ  1.72                          Pro – β               27.72 
    Pro – β  1.95                                    Tyr – β                 34.61 
    Tyr – β    2.91                                              Pro – δ              44.43 
    Pro – δ  3.26                                       Tyr – α               55.89 
    Pro – α  4.04                                              Pro – α               58.27 
    Tyr – α  4.24            Tyr – Ar             114.66 
    Tyr – Ar    6.63                                              Tyr – Ar             126.92 
    Tyr – Ar    7.04                                             Tyr – Ar             130.69 
    Tyr – NH    7.84            Tyr – Ar             156.68 
    Tyr-OH                 9.20                                             Pro – C=O             164.98 
                                                                                                Tyr – C=O             168.78    
                                                             
                                                                                                                                                                     
         
 
 
Figure 3.10  13C NMR (100.61 MHz) spectrum of cyclo(Phe-Pro) in DMSO-d6.  
ppm 
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Figure 3.11  13C NMR (100.61 MHz) spectrum of cyclo(Tyr-Pro) in DMSO-d6. 
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Figure 3.12  1H-1H correlation spectrum (COSY) of cyclo(Phe-Pro) DMSO-d6. 
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Figure 3.13  1H-13C correlation spectrum (HETCOR) of cyclo(Phe-Pro) in DMSO-d6. 
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Figure 3.14  1H-1H correlation spectrum (COSY) of cyclo(Tyr-Pro) DMSO-d6. 
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Figure 3.15  1H-13C correlation spectrum (HETCOR) of cyclo(Tyr-Pro) in DMSO-d6. 
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3.5  CONFORMATIONAL ANALYSIS 
A conformational search is an analytical procedure used to study the configuration of atoms 
as well as the relative molecular energies that result from rotation about any of the single 
bonds in a molecule.  It permits the chemist to predict the drugs’ three-dimensional shape as 
seen by the receptor.  The actual possibilities of atom arrangements in space are called 
conformational isomers or conformers.  A molecular dynamics simulation is used for a 
conformational search and can provide a relatively quick assessment of low energy 
conformers, although the time factor is largely dependent on the processor speed.   
 
Conformational analysis of cyclo(Phe-Pro) and cyclo(Tyr-Pro) was carried out on a Compaq 
Presario Workstation (860 MHz Intel based processor) with HyperChem® (Professional 
version 5.1) molecular modelling software for Windows.  The resultant conformers were 
overlayed with each other in order to ascertain which two would provide the lowest root-
mean-square (RMS) error.  This was done using RMS overlay with HyperChem® software.  
The parameters used to define the conformational search are shown in Table 3.6. The 
overlay of cyclo(Phe-Pro) and cyclo(Tyr-Pro) conformers is shown in Figure 3.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16  RMS overlay of cyclo(Phe-Pro) (green) with cyclo(Tyr-Pro) (blue).  (RMS error = 1.603512). 
Lowest energy conformers: cyclo(Phe-Pro), 6.80782 kcal/mol; cyclo(Tyr-Pro), 14.65729 kcal/mol. 
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        Table 3.6 Conformational search parameters for cyclo(Phe-Pro) and cyclo(Tyr-Pro). 
                      
         Type of search                                                     Usage directed  
 
               Acceptance energy criterion                         Maximum of 50 kcal/mol above the rest 
 
               Pre-optimization check                                  Skip if atoms are closer than 0.5 Ǻ 
                                                                                      Skip if torsions are within 5° of previous 
 
               Duplication tests                                                  
               Duplicates if:                                                 Energy is within 0.05 kcal/mol  
                                                                                     RMS error within 0.25 
                                                                            
               Optimization Termination                            RMS gradient = 0.01 kcal/Å.mol-1 
                                                                        Maximum cycles 1000 
 
               Limits                                                            10000 iterations OR 
                                                                                      1000 optimizations 
                                                                        Do not keep more than 10 conformations 
 
 
 
 
 
In summary, cyclo(Phe-Pro) and cyclo(Tyr-Pro) were synthesized in high yields and shown 
to be free of phenol contamination.  Physicochemical characterization by TLC and thermal 
analysis showed the CDPs to be chemically pure.  Finally, the chemical structures of 
cyclo(Phe-Pro) and cyclo(Tyr-Pro) were verified by structural elucidation using IR 
spectroscopy, MS and NMR spectroscopy.  The two CDPs synthesized in the present study 
were thus considered to be suitable for biological studies investigating the effects on cancer 
cells in vitro. 
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CHAPTER 4: EFFECTS OF CYCLIC DIPEPTIDES ON CELL       
GROWTH AND VIABILITY 
 
 
4.1  INTRODUCTION 
The optical and fluorescent staining of cellular macromolecules in 96-well microtiter plates 
has emerged as the most convenient method for quantifying cell growth and cytotoxicity in 
vitro (Skehan, 1998).  The sulforhodamine B (SRB) optical density assay of cell culture 
protein was developed at the U.S. National Cancer Institute (NCI) for cell-based high 
throughput anticancer drug discovery screening (Skehan et al., 1990).  In the present study 
the SRB assay was employed using the NCI’s 1 + 2 day screening protocol in which cells are 
seeded, allowed a 1-day recovery period and then incubated with test compounds for an 
additional 2 days (Monks et al., 1991).  The SRB assay was used to investigate the effects of 
the CDPs on the growth of HT-29, HeLa and MCF-7 cancer cell lines.   
 
As recommended by Freshney (2000), the MTT assay, which gives a measure of the number 
of viable cells within a population, was used to confirm the SRB assay results.  For the MTT 
assay, only those cyclic dipeptides that exhibited the highest growth inhibition were studied, 
using a longer incubation time of 3 days (72 hours).  The MTT assay was used to investigate 
the effects of CDPs on the viability or survival of HT-29, HeLa, MCF-7 and WHCO3 cell 
lines.  The WHCO3 cell line was adapted to growth conditions in our laboratory at a much 
later stage in the study and was therefore only investigated by using the MTT assay protocol. 
Where specific sections of this work have been accepted for publication, reference is made 
to Brauns et al. (2004).   
 
In order to determine whether the potential growth inhibitory activity of the CDPs was 
selective towards tumour cells, while having little or no effect on cells of a normal 
phenotype, the MTT assay was applied to differentiated Caco-2 cells treated with the cyclic 
dipeptide that exhibited the highest growth inhibition.  Caco-2 cells, which are of colonic 
origin, are able to spontaneously differentiate under standard culture conditions (Pinto et al., 
1983).  They have been extensively characterized with intestinal epithelial markers of 
differentiation, receptors, channels and enzymes typical of xenobiotic transport and 
metabolism (Boulenc, 1997; Meunier et al., 1995; Chantret et al., 1988; Grasset et al., 1984).  
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The Caco-2 cell line is currently established as the standard for intestinal research.  
Furthermore, Velarde et al. (1999) reported the use of the Caco-2 cell line as a model of the 
intestinal epithelium for toxicity screening of various chemical substances, using the MTT 
assay.   
 
 
4.2  MATERIALS AND METHODS 
      
4.2.1  Routine Cell Culture 
HT-29, HeLa and MCF-7 cell lines were purchased from Highveld Biological (Kelvin, South 
Africa).  The WHCO3 cell line was kindly provided by Professor A Thornley (Department 
of Zoology, University of the Witwatersrand, Johannesburg, South Africa).  Cells, in 10 cm 
culture dishes, were cultured without antibiotics in RPMI 1640 medium (Sigma, Germany) 
containing 10% heat-inactivated fetal calf serum (FCS), 25 mM HEPES and 2 mM 
glutamine (Highveld Biological, South Africa) in a humidified 5% CO2 incubator at 37°C.   
The cell growth medium was replaced every 48 hours and cells were passaged at 70-80% 
confluence.   
 
4.2.2 SRB Cell Growth Assay 
SRB is a bright pink aminoxanthene dye with two sulfonic acid groups.  Under mildly acidic 
conditions, it binds electrostatically to the basic amino acid residues of trichloroacetic acid 
(TCA)-fixed cells, serving as a quantitative colorimetric stain for cell culture protein.  The 
histochemistry of SRB is similar to that of related dyes, such as Coomassie brilliant blue and 
naphthol yellow S, which are used widely as protein stains (Skehan et al., 1990).     
 
4.2.2.1 SRB Growth Curves 
Growth curves were set up for each cell line to determine the appropriate seeding density to 
be used for experiments.  For each cell line, cells were seeded into 96-well microtiter plates 
at increasing densities from 1 600 to 16 000 cells per well in 200 µl of growth medium.  From 
the growth curves, a seeding density was selected for each cell line that produced an optical 
density (OD) signal between 0.2-2.0 OD units (linear range of the SRB assay) after 24 hours 
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(pre-incubation period) and 72 hours (24 hours pre-incubation + 48 hours exposure to 
CDPs).    
 
4.2.2.2 Cell Exposure to CDPs 
Cells were seeded into 96-well microtiter plates at an appropriate cell density, and pre-
incubated for 24 hours at 37°C to allow stabilization prior to addition of the peptides.    
After 24 hours, spent growth medium was removed from the cells and replaced with 200 µl 
of the appropriate CDP preparation.  CDPs were dissolved in DMSO, diluted in RPMI 1640 
medium (with 10%, v/v, FCS) and used immediately.  Five dilutions of each CDP were 
prepared to give final concentrations of 10, 5, 1, 0.5 and 0.1 mM.  The final DMSO 
concentration in the experiments did not exceed 0.5% (v/v) and separate controls included 
an equal percentage of DMSO.  Melphalan (Sigma), a standard cytotoxic drug, was included 
as a positive control at a final concentration of 0.1 mM (Monks et al., 1991).  A schematic 
outline of the 3-day SRB assay protocol is shown in Figure 4.1. 
 
 
 
 
 
 
 
 
 
Figure 4.1  Schematic outline of the major features of the SRB assay protocol, as described in sections 4.2.2.2             
and 4.2.2.3.  
 
 
4.2.2.3 SRB Assay  
After 48 hours of exposure to the CDPs, the SRB assay was performed as previously 
described (Skehan et al., 1990).  Cells were fixed in situ by gently layering 50 µl of cold 50% 
(w/v) TCA (4°C) on top of the growth medium in each well to produce a final TCA 
concentration of 10%.  The cultures were incubated for 60 min at 4°C and then washed five 
times with tap water.  Plates were air dried and stained with SRB (Sigma) (0.4%, w/v, in 1%, 
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v/v, acetic acid) for 10 minutes at room temperature.  At the end of the staining period, SRB 
was removed and cultures were quickly rinsed four times with 1% acetic acid, poured from a 
beaker directly into the culture wells, to remove unbound dye.  After rinsing, plates were air 
dried until no standing moisture was visible.  Bound dye was solubilized with 10 mM 
unbuffered Tris base (pH 10.5).  The optical densities were read at 540 nm using a Multiskan 
MS microtiter plate reader (Labsystems, Finland).  A measure was also made of the cell 
population density at time zero, T0 (the time at which drugs are added) from an extra 
reference plate of inoculated cells fixed with TCA just prior to drug addition to the test 
plates.  Background optical densities were measured in wells containing growth medium 
without cells, and drug blanks were measured in wells containing CDPs and growth medium 
only.   
 
4.2.2.4 Analysis and Calculations of Cellular Response 
From the SRB assay three measurements were obtained: control optical density (C), test 
optical density (T) and optical density at time zero (T0).  The following formula was used to 
calculate the growth of test samples as a percentage of control cell growth, with T greater 
than or equal to T0: 
100 x [(T-T0)/(C-T0)] 
 
 
4.2.3 MTT Cell Viability Assay 
The MTT assay is based on the metabolic reduction of the yellow tetrazolium salt 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) to a water-insoluble, 
dark blue formazan product.  This conversion only takes place in living cells.  The formazan 
product may be dissolved in DMSO.  The optical density is measured 
spectrophotometrically, yielding absorbance as a function of concentration of converted dye, 
which directly correlates to the number of metabolically active cells in the culture 
(Carmichael et al., 1987).     
 
Formazan production in tetrazolium-based assays for cell viability may be affected by a 
number of parameters within the culture environment and MTT reduction may vary 
significantly between cell lines.  In particular, it has been shown that transport and constant 
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intracellular metabolism of D-glucose are required for optimal MTT reduction.  Cell lines 
that metabolise the sugar extensively (for example, HT-29), exhibit a large decrease in the 
production of MTT formazan (Vistica et al., 1991).  In the present study, MTT formazan 
production and cell growth characteristics were investigated for each cell line before testing 
the effects of CDPs on the cells.  In addition, melphalan was used at varying concentrations 
to compare a 48-hour exposure time (SRB assay) to the proposed 72-hour exposure time for 
the MTT assay.  This was done to investigate whether formazan production by HT-29 cells 
may be affected by D-glucose metabolism over a longer exposure time, which could result in 
the underestimation of the effects of CDPs on cell survival.  
  
4.2.3.1 MTT Reduction as a Function of Cell Number 
To determine the relationship of cell number to MTT formazan production, cells were 
counted using a haemocytometer, seeded at increasing cell densities into a 96-well microtiter 
plate and processed by the MTT assay.  HT-29, MCF-7, HeLa, and WHCO3 cells were 
seeded at increasing cell densities from 2 500 to 80 000 cells per well.  Caco-2 cells were 
seeded up to 100 000 cells per well.  Cells were allowed to attach to the substratum over a 30 
min incubation period at 37°C, after which the MTT formazan production was measured 
according to the method of Alley et al. (1988) (section 4.2.3.4).   
 
4.2.3.2 MTT Growth Curves 
Growth curves were set up for HT-29, MCF-7, HeLa and WHCO3 cells to determine the 
optimal seeding densities that would yield maximal absorbance while ensuring that cells 
remained in exponential growth during the experiments.  Each cell line was seeded at varying 
cell densities, including 2 000, 4 000 and 8 000 cells per well.  MTT formazan production 
was measured every 24 hours over a period of 4 days (24 hours pre-incubation + 72 hours 
exposure to CDPs).  Growth curve analysis was not required for Caco-2 cells as the cells 
were grown to confluence before the addition of test compound (see section 4.2.3.3).   
 
4.2.3.3 Cell Exposure to CDPs 
Cells were seeded into 96-well microtiter plates at an appropriate cell density and pre-
incubated for 24 hours at 37°C to allow stabilization prior to addition of the peptides.    
After 24 hours, the spent growth medium was removed from the cells and replaced with 200 
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µl of the appropriate CDP preparation.  CDPs were dissolved in DMSO, diluted in RPMI 
1640 medium (with 10%, v/v, FCS) and used immediately.  Six dilutions of each CDP were 
prepared to give final concentrations of 10, 5, 1, 0.2, 0.04 and 0.008 mM.  Cyclo(Tyr-Pro) 
was not available at the time of conducting the dose-response experiments and was only 
tested at 10 mM at a later stage with the SRB assay.  The final DMSO concentration in the 
experiments did not exceed 0.5%, v/v, and separate controls included an equal percentage of 
DMSO.   Cells were incubated with CDPs for 72 hours.  A schematic outline of the 4-day 
MTT assay protocol is shown in Figure 4.2.  For the melphalan inhibition curves, comparing 
48 hours to 72 hours exposure, HT-29 cells were seeded as described above and melphalan 
was added to the cells at a concentration range of 0.0016 to 1 mM. 
 
For toxicity assays using the Caco-2 cell line, Caco-2 cells were seeded at 50 x 103 cells/well 
and left in culture for 48 hours to allow time for spontaneous differentiation.  The 
appropriate CDP was added at 10 mM and the plate was incubated for 18 hours (Velarde et 
al., 1999).  The cellular response was determined by the MTT assay as described for all other 
experiments (section 4.2.3.4). 
 
 
 
 
 
 
 
Figure 4.2  Schematic outline of the major features of the MTT assay protocol, as described in sections 4.2.3.3 
and 4.2.3.4.  
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method of Alley et al. (1988).  The spent growth medium was removed from all the 
microtiter plate wells by aspiration.  A stock solution of MTT (5 mg/ml in PBS) was diluted 
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in growth medium to a final concentration of 0.5 mg/ml and 200 µl of the working solution 
was added to all the wells.  After an incubation period of 3 hours at 37°C, the supernatant 
was removed by aspiration and the formazan product was dissolved in DMSO.  Plates were 
agitated on a plate shaker and the optical densities were read at 540 nm (Multiskan MS, 
Labsystems).  Background optical densities were measured in wells containing growth 
medium without cells, and drug blanks were measured in wells containing test compound 
and growth medium only.  The cellular response for the MTT assay was calculated as % T/C 
[(OD of treated cells/OD of control cells) x 100], a measure of cell viability and survival in 
the presence of test compound. 
 
4.2.4  Statistical Analysis 
Each data point in any experiment represents the mean ± standard deviation (SD) of at least 
triplicate determinations, representative of at least two independent experiments, unless 
otherwise specified.  Error bars are shown on the figure when larger than the diameter of the 
symbol.  Differences between treated and control cultures or between different cell lines, 
were analysed using the two-sample Student’s t-test.  Significant differences are indicated by 
p values of <0.05 or <0.01 where applicable.  IC50 values were determined by analysing 
sigmoid dose-response inhibition curves using GraphPad Prism software (version 4.0). 
   
4.3  RESULTS  
 
4.3.1  SRB Growth Curves 
The growth curves of HT-29, HeLa and MCF-7 cells, determined at varying cell densities, 
are shown in Figures 4.3, 4.4 and 4.5, respectively.  Based on the growth curves, the 24- to 
72-hour interval was used to determine the optimal seeding density that yielded an OD 
signal between 0.2-2.0 OD units.  For the HT-29 (Figure 4.3) and MCF-7 (Figure 4.5) cell 
lines, a seeding density of 6 400 cells/well was selected.  For the HeLa cell line (Figure 4.4) a 
seeding density of 3 200 cells/well was selected.  At these seeding densities the cell growth 
remained linear up to 72 hours post-seeding. 
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Figure 4.3  Growth curves for the HT-29 colon cancer cell line at various seeding densities, as measured by the 
SRB assay.  Results are expressed as the mean ± SD of quadruplicate determinations in one experiment. 
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Figure 4.4  Growth curves for the HeLa cervical cancer cell line at various seeding densities, as measured by the 
SRB assay.  Results are expressed as the mean ± SD of quadruplicate determinations in one experiment. 
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Figure 4.5  Growth curves for the MCF-7 breast cancer cell line at various seeding densities, as measured by the 
SRB assay.  Results are expressed as the mean ± SD of quadruplicate determinations in one experiment. 
 
 
4.3.2 Effects of CDPs on Cell Growth – SRB Assay 
The growth of cells treated with CDPs was calculated as a percentage of control cell growth 
and plotted against the concentration of CDP used.  The dose-response curves for each 
CDP are shown in Figures 4.6 to 4.11.  Cyclo(Phe-Pro) (Figure 4.6) was the only CDP that 
exhibited a typical sigmoid dose-response curve, as expected for growth inhibition or 
cytotoxicity (Freshney, 2000).  Cyclo(Phe-Pro) exhibited significant growth inhibition at 
concentrations of 5 mM (p<0.01) and 10 mM (p<0.01) in all three cell lines.  The IC50 values 
for cyclo(Phe-Pro) were 5.24 ± 1.25 mM in HT-29,  3.85 ± 1.26 mM in HeLa and  5.07 ± 
1.32 mM in MCF-7 cells.   
 
Cyclo(Gly-Pro) (Figure 4.7), Cyclo(Pro-Pro) (Figure 4.8), cyclo(Leu-Pro) (Figure 4.9) and  
cyclo(His-Pro) (Figure 4.10) exhibited only marginal growth inhibitory effects (p<0.05), 
predominantly at the highest concentration used (10 mM).  Cyclo(Thr-Pro) (Figure 4.11) did 
not exhibit significant growth inhibition (p>0.05) in any of the cell lines.  The comparative 
growth inhibitory effects for all the CDPs tested at 10 mM, including cyclo(Tyr-Pro), is 
shown in Figure 4.12 (Brauns et al., 2004).  Cyclo(Phe-Pro) exhibited the greatest growth 
 73
inhibitory effect (p< 0.01) on the three cell lines.  MCF-7 cells were more susceptible than 
HT-29 and HeLa cells to treatment with cyclo(Tyr-Pro) (p<0.01).  Although the other cyclic 
dipeptides, except for cyclo(Thr-Pro), exhibited marginal growth inhibition, only cyclo(Phe-
Pro) and cyclo(Tyr-Pro) were subsequently used to confirm their growth inhibitory effects 
by using the MTT assay (Brauns et al., 2004).      
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Figure 4.6  The effect of cyclo(Phe-Pro) on cell growth in HT-29, HeLa and MCF-7 cells, as determined by  the 
SRB assay.  Results are expressed as the mean ± SD of quadruplicate determinations, representative of two 
independent experiments.  Significant differences are not indicated for the sake of clarity. 
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Figure 4.7  The effect of cyclo(Gly-Pro) on cell growth in HT-29, HeLa and MCF-7 cells, as determined by the 
SRB assay.  Results are expressed as the mean ± SD of quadruplicate determinations, representative of two 
independent experiments.  Significant differences are not indicated for the sake of clarity. 
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Figure 4.8  The effect of cyclo(Pro-Pro) on cell growth in HT-29, HeLa and MCF-7 cells, as determined by the 
SRB assay.  Results are expressed as the mean ± SD of quadruplicate determinations, representative of two 
independent experiments.  Significant differences are not indicated for the sake of clarity. 
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Figure 4.9  The effect of cyclo(Leu-Pro) on cell growth in HT-29, HeLa and MCF-7 cells, as determined by the 
SRB assay.  Results are expressed as the mean ± SD of quadruplicate determinations, representative of two 
independent experiments.  Significant differences are not indicated for the sake of clarity. 
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Figure 4.10  The effect of cyclo(His-Pro) on cell growth in HT-29, HeLa and MCF-7 cells, as determined by 
the SRB assay.  Results are expressed as the mean ± SD of quadruplicate determinations, representative of two 
independent experiments.  Significant differences are not indicated for the sake of clarity. 
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Figure 4.11  The effect of cyclo(Thr-Pro) on cell growth in HT-29, HeLa and MCF-7 cells, as determined by 
the SRB assay.  Results are expressed as the mean ± SD of quadruplicate determinations, representative of two 
independent experiments. 
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Figure 4.12 Effects of proline-based CDPs (10 mM) on the growth of HT-29, HeLa and MCF-7 cells.    
Melphalan (0.1 mM) was included as a positive control.  Results are expressed as means ± SD of three 
independent experiments, each performed in quadruplicate. *, p<0.01; **, p<0.05 (compared to control cells); 
#, p<0.01 (for MCF-7 cells compared to HT-29 and HeLa cells). c, cyclo. 
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4.3.3  MTT Reduction as a Function of Cell Number 
The amount of formazan product generated and then measured after solubilization in 
DMSO was proportional to cell number for HT-29 (Figure 4.13), HeLa (Figure 4.14), MCF-
7 (Figure 4.15), WHCO3 (Figure 4.16) and Caco-2 cells (Figure 4.17).  These data were 
generated by seeding cells at the inoculum noted on the x-axis and processing the plates after 
a 3-hour incubation with MTT.  There was good reproducibility between quadruplicate wells 
with standard deviations ≤ 5%.   As expected, the absolute absorbance for a given cell 
number varied between cell lines (Carmichael et al., 1987).  For each cell line there was a 
deviation in linearity beyond 20 000 cells/well.  These results are comparable to those of 
Carmichael et al. (1987) in which a non-linear relationship was obtained for NCI-H249 and 
NCI-H460 human lung cancer cell lines.   
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Figure 4.13 MTT reduction as a function of cell number in HT-29 colon cancer cells, as determined within a  
96-well microtiter plate. Results are expressed as the mean ± SD of quadruplicate determinations, 
representative of two independent experiments. 
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Figure 4.14  MTT reduction as a function of cell number in HeLa cervical cancer cells, as determined within a 
96-well microtiter plate. Results are expressed as the mean ± SD of quadruplicate determinations, 
representative of two independent experiments. 
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Figure 4.15  MTT reduction as a function of cell number in MCF-7 breast cancer cells, as determined within a 
96-well microtiter plate. Results are expressed as the mean ± SD of quadruplicate determinations, 
representative of two independent experiments. 
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Figure 4.16  MTT reduction as a function of cell number in WHCO3 oesophageal cancer cells, as determined  
within a 96-well microtiter plate. Results are expressed as the mean ± SD of quadruplicate determinations, 
representative of two independent experiments. 
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Figure 4.17 MTT reduction as a function of cell number in Caco-2 cells, as determined within a 96-well  
microtiter plate. Results are expressed as the mean ± SD of quadruplicate determinations, representative of two 
independent experiments. 
 
 
4.3.4 MTT Growth Curves 
The growth curves for HT-29, HeLa, MCF-7 and WHCO3 cancer cell lines are shown in 
Figures 4.18, 4.19, 4.20 and 4.21, respectively.  There was good reproducibility between 
quadruplicate wells with standard deviations ≤ 10%.  These results are comparable to MTT 
growth curve analysis as reported by Carmichael et al. (1987) on lung cancer cells lines using 
cell densities between 500 and 10 000 cells/well.  Based on the growth curves obtained in 
the present study, optimal seeding densities were selected with respect to subsequent 
experiments on the exposure of cells to CDPs.  For the HT-29 and MCF-7 cell lines, a 
seeding density slightly higher than 4 000 cells/well (i.e. 5 000 cells/well) was selected.  For 
the HeLa cell line, a seeding density of 2 000 cells/well was selected.  For the WHCO3 cell 
line, a seeding density between 4 000 and 8 000 cells/well (i.e. 6 000 cells/well) was selected.  
The use of 5 000 cells/well as an initial seeding density for HT-29 cells has previously been 
reported by Monks et al. (1991).  
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Figure 4.18  MTT growth curves for the HT-29 colon cancer cell line, at different seeding densities.  Results are 
expressed as the mean ± SD of quadruplicate determinations, representative of two independent experiments. 
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Figure 4.19  MTT growth curves for the HeLa cervical cancer cell line, at different seeding densities.  Results 
are expressed as the mean ± SD of quadruplicate determinations, representative of two independent 
experiments. 
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Figure 4.20  MTT growth curves for the MCF-7 breast cancer cell line, at different seeding densities.  Results 
are expressed as the mean ± SD of quadruplicate determinations, representative of two independent 
experiments. 
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Figure 4.21  MTT growth curves for the WHCO3 oesophageal cancer cell line, at different seeding densities.  
Results are expressed as the mean ± SD of quadruplicate determinations, representative of two independent 
experiments. 
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4.3.5 Melphalan Inhibition Curves 
The comparison of a 72-hour and a 48-hour exposure of HT-29 cells to melphalan is shown 
in Figure 4.22.  The HT-29 cell line was specifically chosen for this comparison because 
these cells are known to metabolise D-glucose extensively, which results in a decrease in 
MTT reduction with time (Vistica et al., 1991).  This was of particular importance in the 
present study because the cell growth medium was not replaced during exposure to CDPs.  
Figure 4.22 shows that the use of a longer exposure time of 72 hours compared to 48 hours 
did not result in a decrease in MTT formazan production, or an underestimation of growth 
inhibition.  There was no significant difference between the IC50 values for the 72-hour 
exposure (0.219 ± 0.136 mM) and that of the 48-hour exposure (0.313 ± 0.142 mM).  A 72-
hour exposure to CDPs was therefore used in subsequent experiments.  This approach was 
consistent with that recommended by Alley et al. (1988) for continuous drug exposure 
experiments.    
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Figure 4.22  MTT analysis of growth inhibition by melphalan, comparing a 72-hour to a 48-hour exposure in 
HT-29 cells.  Results are expressed as the mean ± SD of quadruplicate determinations, representative of two 
independent experiments. 
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4.3.6 Effects of CDPs on Cell Viability – MTT Assay 
The dose-response curves for the continuous exposure of HT-29, HeLa, MCF-7 and 
WHCO3 cell lines to cyclo(Phe-Pro) and cyclo(Tyr-Pro) are shown in Figures 4.23 and 4.24, 
respectively.  Results are expressed as the absorbance of treated cells as a percentage of the 
absorbance of control cells.  Figure 4.23 shows a dose-dependent growth inhibition of HT-
29, HeLa, MCF-7 and WHCO3 cells after treatment with cyclo(Phe-Pro).  The comparison 
of IC50 values for cyclo(Phe-Pro) observed for the MTT and SRB assays is shown in Table 
4.1.  There were no significant differences between the IC50 values for the MTT and SRB 
assays and the results obtained for the two assays are thus considered to be comparable.  
These results are consistent with that of Rubinstein et al. (1990), who compared the IC50 
values obtained for the MTT and SRB assays of 197 compounds in 38 human tumour cell 
lines.  Interestingly, cyclo(Tyr-Pro) (Figure 4.24) at 10 mM exhibited a greater growth 
inhibitory effect (p<0.01) in MCF-7 and WHCO3 cells compared to HT-29 and HeLa cells. 
 
 
Table 4.1 Comparison of IC50 (mM) values for cyclo(Phe-Pro) observed for the MTT and SRB assays.  Growth 
inhibition curves in Figures 4.6 (SRB assay) and 4.23 (MTT assay) were analysed using GraphPad Prism 
software (version 4.0) and values are reported as IC50 ± SD.  
 
 
Cell line  MTT assay    SRB assay   
 
HT-29  4.04 ± 1.15             5.24 ± 1.25 
HeLa  2.92 ± 1.55             3.85 ± 1.26 
MCF-7  6.53 ± 1.26             5.07 ± 1.32 
WHCO3 5.19 ± 1.13                  ND 
                                   
                                 ND, not determined 
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Figure 4.23  The effects of cyclo(Phe-Pro) on the growth of HT-29, MCF-7, HeLa, and WHCO3 cells, as 
measured by the MTT assay after a 72-hour exposure to the CDP.  Results are expressed as means ± SD of 
quadruplicate determinations, representative of three independent experiments.  Significant differences are not 
indicated for the sake of clarity. 
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Figure 4.24  The effects of cyclo(Tyr-Pro) on the growth of HT-29, MCF-7, HeLa, and WHCO3 cells, as 
measured by the MTT assay after a 72-hour exposure to the CDP.  Results are expressed as means ± SD of 
quadruplicate determinations, representative of three independent experiments. *, p < 0.01 for MCF-7 and 
WHCO3 cells compared to HT-29 and HeLa cells. 
*
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4.3.7 Toxicity Testing Using Differentiated Caco-2 cells 
The results shown in Table 4.2 indicate that 10 mM cyclo(Phe-Pro) and cyclo(Tyr-Pro) had 
no significant growth-inhibitory effects on differentiated Caco-2 cells.  Although these 
results need to be confirmed in other intestinal cancerous and normal cells, it is tempting to 
propose that the presence of such selective CDPs in the diet may prevent the development 
of tumours by interfering with the growth of pre-neoplastic lesions while having little effect 
on normal cells.   
 
Table 4.2  MTT toxicity analysis of cyclo(Phe-Pro) and cyclo(Tyr-Pro)(10 mM) in differentiated Caco-2 cells.  
Results are expressed as the mean ± SD of quadruplicate determinations, representative of two independent 
experiments.  
 
                                      cyclo(Phe-Pro)           cyclo(Tyr-Pro)   
 
                                   % of Control Absorbance        94.14 ± 3.62                 97.22 ± 2.03 
  
 
 
4.4  DISCUSSION 
 
The effects of seven proline-based CDPs on the growth of HT-29 (colon), MCF-7 (breast), 
and HeLa (cervical) cancer cells, were investigated by using the SRB assay as an initial phase 
of screening.  In summary, results (Figure 4.12) show that cyclo(Phe-Pro) distinctly exhibited 
the greatest growth-inhibitory effect  on the three cell lines compared to the other CDPs 
(p<0.01) (Brauns et al., 2004).  It could be speculated that the activity of cyclo(Phe-Pro) may 
be attributable, in part, to the greater hydrophobicity of the phenylalanine side chain 
compared to the side chains of the other six CDPs.  The widely observed relationship 
between drug activity and log Kow (octanol-water partition coefficient), where drug activity 
increases with hydrophobicity, is thought to be due to an absorption of the compound into 
biological membranes which are themselves hydrophobic (Van Wezel and Opperhuizen, 
1995).  This suggestion correlates with the fact that cyclo(Thr-Pro) (Figure 4.12), which has 
the most polar (least hydrophobic) side chain among the group of seven CDPs, was the only 
CDP that did not exhibit significant growth inhibition (p>0.05) in any of the cell lines.   
 
It could also be speculated that the activity of cyclo(Phe-Pro) may be attributable to the 
specific three-dimensional conformation of the compound in the cellular environment. For 
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instance, Kanoh et al. (1999) reported a 33-100 fold difference in antitumour activity between 
the (+) and (–) enantiomers of phenylahistin (Figure 1.3, section 1.2.5, Chapter 1), 
demonstrating that the stereochemistry of the α-carbon of the phenylalanine residue was 
important for the antitumour activity.  Furthermore, it could be suggested that the activity of 
cyclo(Phe-Pro) may be due to a combination of both transportability and conformational 
characteristics.   
 
Interestingly, cyclo(Tyr-Pro) (Figure 4.12) exhibited a greater growth-inhibitory effect on 
MCF-7 cells as compared to its effects on HT-29 or HeLa cells.  The overall effects of 
cyclo(Tyr-Pro), however, were significantly less (p<0.01) than those of cyclo(Phe-Pro) 
(Brauns et al., 2004). Of the remaining CDPs, namely cyclo(Gly-Pro), cyclo(Pro-Pro), 
cyclo(Leu-Pro) and cyclo(His-Pro), there were no significant differences between the 
respective effects on cell growth in any of the cell lines (Figure 4.12).  These results are 
comparable to a previous report on the cytotoxic effects of bile salts with differing 
physicochemical properties (Schlottmann et al., 2000).  The unconjugated hydrophobic bile 
salt deoxycholate exhibited a strong cytotoxic effect on HT-29 cells, whereas the conjugated 
bile salt glycodeoxycholate and the trihydroxy bile salt cholate did not exhibit cytotoxicity 
(Schlottmann et al., 2000).  
 
The effects of cyclo(Phe-Pro) and cyclo(Tyr-Pro), as determined by using the SRB assay,  
were subsequently confirmed by the MTT assay using a longer exposure time of 72 hours, 
and extending the investigation to a fourth cell line, namely the WHCO3 human 
oesophageal cancer cell line.  Once again, cyclo(Phe-Pro) (Figure 4.23) exhibited pronounced 
growth-inhibitory effects on HT-29, HeLa and MCF-7 cells (Brauns et al., 2004), as well as 
on WHCO3 cells.  The IC50 values for cyclo(Phe-Pro) observed for the MTT assay 
compared favourably with those observed for the SRB assay (Table 4.1).  Cyclo(Tyr-Pro) 
(Figure 4.24) exhibited significantly less growth inhibition (p<0.01) than cyclo(Phe-Pro).  
Nevertheless, it was interesting to note that cyclo(Tyr-Pro) at 10 mM exhibited greater 
growth inhibition (p<0.01) in MCF-7 and WHCO3 cells, as compared to HT-29 and HeLa 
cells.   
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In order to determine the effects of CDPs on cells of a normal phenotype, the MTT assay 
was applied to differentiated Caco-2 cells that were exposed to 10 mM cyclo(Phe-Pro) or 
cyclo(Tyr-Pro).  Post-confluent cultures of Caco-2 cells undergo spontaneous differentiation, 
and subsequently display characteristic features of normal epithelial cells of the 
gastrointestinal tract (Pinto et al., 1983).  The cell line is currently established as the standard 
for intestinal research (Velarde et al., 1999).  The lack of significant growth inhibition by 10 
mM cyclo(Phe-Pro) and cyclo(Tyr-Pro) in differentiated Caco-2 cells (Table 4.2, section 
4.3.7) suggests that these CDPs may be selective towards killing cancer cells while having 
little effect on normal cells.  Selective toxicity of other dietary factors, such as glucosinolate 
hydrolysis products, has previously been reported in HT-29 versus differentiated Caco-2 
cells (Gamet-Payrastre et al., 1998). 
 
Due to the pronounced growth-inhibitory effects observed for cyclo(Phe-Pro), this CDP 
was selected to study the potential to induce apoptosis in HT-29 cells in order to establish an 
underlying mechanism of action.     
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CHAPTER 5: INDUCTION OF APOPTOSIS 
 
5.1  INTRODUCTION 
 
Various criteria were used to evaluate the induction of apoptosis in response to cyclo(Phe-
Pro) treatment of HT-29 colon cancer cells.  General morphological features of apoptosis 
were examined by phase-contrast microscopy, and a more detailed inspection of chromatin 
condensation and nuclear fragmentation were performed using fluorescence microscopy to 
establish whether the typical features of cells undergoing apoptosis may be induced by 
treatment with cyclo(Phe-Pro).  Morphology remains the definite criterion for apoptosis 
(Kass and Jones, 2000).   
 
Subsequent experiments were used to investigate characteristic biochemical alterations in the 
progression of the apoptosis cascade.  These experiments were performed in order to 
support the morphological analysis, and to elucidate key molecular events that may be 
triggered by cyclo(Phe-Pro) treatment in HT-29 cells.  It was also important to determine 
how closely cyclo(Phe-Pro)-induced cell death in HT-29 cells correlated with the somewhat 
predictable pattern of apoptotic cell death observed in other models of drug-induced 
apoptosis (Ruemmele et al., 1999; Sun et al., 1999; Medina et al., 1997; Kerr et al., 1994), 
particularly in light of the recent emergence of alternative, caspase-independent cell death 
pathways (Leist and Jäättelä, 2001).   
 
Biochemical analysis of apoptosis induction included the investigation of phosphatidylserine 
(PS) externalisation (translocation), detection of PARP cleavage, and assays for caspase-3 
and calpain activity.  Routine cell culture was performed as described in Chapter 4 (section 
4.2.1).  Where specific sections of this work have been accepted for publication, reference is 
made to Brauns et al. (2004).   
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5.2  MATERIALS AND METHODS 
 
5.2.1 Phase-contrast Microscopy 
Cells were plated at a density of 2 × 104 cells/cm2 into a 24 well plate and treated with 5 mM 
cyclo(Phe-Pro) for 24 or 48 hours.  Cells were viewed by phase-contrast light microscopy 
(Nikon, TMS, Japan) and photographs were taken using a Nikon camera (Japan). 
 
5.2.2 Analysis of Chromatin Condensation 
Cells were plated at a density of 2 × 104 cells/cm2 on 13 mm glass coverslips (BDH 
Laboratory Supplies, England) in a 24-well plate and treated with 1 or 5 mM cyclo(Phe-Pro) 
for 4, 12, 24, 48 and 72 hours.  At the end of each treatment, cells were washed twice with 
PBS at room temperature and stained with Hoechst 33342 (Sigma-Aldrich) (10 µg/ml) in 
PBS for 15 min at room temperature in the dark.  Cells were washed once with PBS, placed 
on a microscope slide and analysed immediately using a fluorescence microscope (Olympus 
BX60).  Quantitative assessment was performed by counting 300 cells for each treatment 
and evaluating the percentage of apoptotic cells.  
 
 
5.2.3 Dual Staining with Hoechst 33342 and Annexin V-FITC 
Simultaneous analysis of the presence of PS on the outer leaflet of the cell membrane as well 
as chromatin condensation were performed using a double-labelling experiment with 
annexin V-fluorescein and Hoechst 33342 according to Martin et al. (1996).  In the presence 
of calcium, annexin V is used as a specific probe to bind to phosphatidylserine on the outer 
leaflet of the cell membrane of apoptotic cells (Verhoven et al., 1995).  For this double-
labelling experiment HT-29 cells were grown on coverslips as described in section 5.2.2 and 
treated with 5 mM cyclo(Phe-Pro) for 48 hours.  Cells were simultaneously stained with 
Hoechst 33342 and annexin V-fluorescein (Annexin-V-FLUOS staining kit, used according 
to manufacturer’s instructions, Roche Diagnostics) and analysed with a fluorescent 
microscope (Olympus BX60) equipped with Hoechst/DAPI and FITC filters (BX FLA). 
 
To discriminate apoptotic from necrotic cells, the Annexin-V-FLUOS staining kit (Roche 
Diagnostics) was also used, according to the manufacturer’s instructions, for dual-labelling of 
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treated cells with propidium iodide (PI) and annexin V-fluorescein.  PI is a DNA dye that is 
excluded from live cells with an intact plasma membrane, but is able to enter and label the 
DNA of cells with a damaged plasma membrane, i.e., necrotic or lysed cells (Darzynkiewicz 
et al., 1997). 
 
5.2.4 Analysis of PARP Cleavage  
PARP is a protein of 113 kDa and is cleaved to produce fragments of 89 kDa and 24 kDa 
(Figure 5.1) in a wide variety of cells undergoing apoptosis (Kaufmann et al., 1993; 
Kaufmann, 1989).  It has been established that caspase-3 can cleave PARP at the sequence 
DEVD216G to produce the 89 and 24 kDa cleavage fragments observed in apoptotic cells 
(Nicholson et al., 1995).  In the present study, exponentially growing HT-29 cells were 
seeded into 35 or 60 mm culture dishes at a density of 4 x 104 cells/cm2 and allowed a 24-
hour recovery period before initiation of experiments.  In one set of experiments, cells were 
treated with 5 and 10 mM cyclo(Phe-Pro) for 24 and 48 hours.  In another set of 
experiments, cells were treated with 10 mM cyclo(Phe-Pro) for 1, 4, 8 and 24 hours to 
examine the time course of PARP cleavage up to 24 hours.    
 
 
     113 kDa 
 
 
 
 
 
Figure 5.1  Schematic representation of human PARP, illustrating the cleavage site for caspase-3 and the 89 and 
24 kDa cleavage products, as well as the F-1-23 monoclonal antibody recognition site.  Adapted from 
Nicholson et al. (1995). 
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5.2.4.1 Preparation of Cell Extracts 
Whole-cell extracts were prepared by direct lysis of PBS-washed cells according to Boucher 
et al. (2001).  Both floating and attached cells (removed by scraping) from one 35 or 60 mm 
dish were collected in spent growth medium, and centrifuged at 250 x g, 4°C, for 10 min.  
The supernatant was discarded and the cells were washed once with 500 µl ice-cold PBS, and 
centrifuged at 500 x g, 4°C, for 5 min.  The supernatant was discarded and the cells were 
resuspended in 500 µl ice-cold PBS.  At this point an aliquot of 30 µl was taken for protein 
determination using the BCA protein assay (a representative calibration curve using BSA as a 
standard is shown in Figure A8, Appendix A).  Cells were centrifuged at 500 x g, 4°C, for 5 
min.  After discarding the supernatant, the cells were lysed in 100 µl of PARP extraction 
buffer [6 M urea, 2% (w/v) SDS, 10% (v/v) glycerol, 62.5 mM Tris-HCl (pH 6.8), 5% (v/v) 
β-mercaptoethanol (freshly added) and 0.3% (w/v) bromophenol blue].  Finally, the cell 
extract was sonicated on ice for 15 seconds (Sonoplus, Bandelin, HD 2200, MS 73 probe).  
Samples were stored at -80°C or directly incubated at 65°C for 15 min before analysis on a 
SDS-PAGE gel. 
 
5.2.4.2 SDS-PAGE and Western Blotting 
For each sample, 20-30 µg of protein was loaded on a 10% polyacrylamide gel, which was 
run with an electrophoresis apparatus (Mini-PROTEAN II, Bio-Rad) in running buffer (25 
mM Tris, 192 mM glycine and 0.1% (w/v) SDS) at 100 V for 1 hour and 15 min.  Proteins 
were transferred to a PVDF membrane in a transblot cell apparatus (Bio-Rad) with pre-
cooled transfer buffer (25 mM Tris, 192 mM glycine and 20% (w/v) methanol).  Transfer 
was performed at 4°C with stirring at 30 V for 16 hours.  Loading equivalence and transfer 
efficiency were monitored by Ponceau S (Sigma) staining of transferred membranes.  
Standard western blotting techniques were used to probe for steady-state protein levels 
according to the manufacture’s instructions for the enhanced chemiluminescence detection 
kit (ECL Western blotting analysis system, Amersham) with minor modifications.   
 
After transfer and Ponceau S staining, PVDF membranes were soaked for 1 hour in 
blocking buffer containing 5% (w/v) non-fat powdered milk in TBS-T buffer [20 mM Tris 
(pH 7.6), 137 mM NaCl and 0.015% (v/v) Tween 20].  Membranes were washed with two 
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quick changes of washing buffer (TBS-T) before the primary antibody was added.  F-1-23 is 
a mouse monoclonal antibody (MAB 3191, Chemicon International) that recognizes the N-
terminal region of PARP.  A schematic representation of human PARP illustrating the F-1-
23 antibody recognition site is shown in Figure 5.1.  The primary antibody was diluted 
1:1000 in TBS-T and incubated with the membranes for 1 hour at room temperature.  The 
membranes were washed with several changes of TBS-T.  The secondary antibody, anti-
mouse coupled to horse-radish peroxidase (ECL Western blotting analysis system, 
Amersham), was added at a dilution of 1:2000 for 1 hour.  The blots were washed with 
several changes of TBS-T.  Proteins of interest were visualized by using the ECL detection 
kit (Amersham) and exposing the membranes to X-ray film (HyperfilmTM, Amersham), for 
periods between 1 and 10 min. 
 
5.2.5 The Effect of a Caspase Inhibitor on PARP Cleavage 
All caspases prefer an Asp at P1 and a Glu at P3 positions in the cleavage site (Boucher et al., 
2001), which has facilitated the synthesis of relatively specific caspase inhibitors.  To further 
investigate the role of caspases in cyclo(Phe-Pro)-induced apoptosis, HT-29 cells were pre-
treated for 1 hour with 50 µM of the broad-range caspase inhibitor, benzyloxycarbonyl-Val-
Ala-Asp-(OMe)-fluoromethylketone (Z-VAD-FMK), before co-administration with 10 mM 
cyclo(Phe-Pro) for 8, 12, 16 and 24 hours.  Preparation of cell extracts and detection of 
PARP cleavage were performed as described in sections 5.2.4.1 and 5.2.4.2. 
 
5.2.6 The Effect of a Calpain Inhibitor on PARP Cleavage 
The calpain inhibitor peptide, a highly specific inhibitor of calpain activity (Maki et al., 1989), 
was used to determine whether calpain activation might play a role in cyclo(Phe-Pro)-
induced PARP cleavage in HT-29 cells.  The cells were pre-treated with 50 µM of the calpain 
inhibitor peptide (Sigma) for 1 hour, before co-administration with 10 mM cyclo(Phe-Pro) 
for 8 and 12 hours. Control cells were incubated with growth medium containing an 
equivalent percentage of DMSO used to dissolve cyclo(Phe-Pro).  Preparation of cell 
extracts and detection of PARP cleavage were performed as described in sections 5.2.4.1 and 
5.2.4.2. 
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5.2.7  Caspase-3 Activity Assay 
The effect of cyclo(Phe-Pro) treatment on caspase-3 activation in HT-29 cells was 
investigated using a fluorometric caspase assay kit (CaspACETM Assay System, Fluorometric, 
Promega, USA).  Caspase-3-like proteases show specificity for cleavage at the C-terminal 
side of the Asp residue of the sequence DEVD.  The kit allowed sensitive, quantitative 
measurement of caspase-3 protease activity using the fluorogenic substrate Ac-DEVD-
AMC.  The substrate was labelled with the fluorochrome 7-amino-4-methyl coumarin 
(AMC).   The kit also included a potent, selective inhibitor of caspase-3 (Ac-DEVD-CHO) 
that was used to assess the specific contribution of caspase-3 activity in the crude cell 
extracts.  For these experiments, HT-29 cells were seeded into 60 mm culture dishes and 
treated with 10 mM cyclo(Phe-Pro) for 8 and 12 hours.  Control cells were incubated with 
growth medium containing an equivalent percentage of DMSO used to dissolve cyclo(Phe-
Pro). 
 
5.2.7.1 Preparation of Cell Extracts 
Floating and attached cells (removed by scraping) were collected from one 60 mm dish in 
spent growth medium and centrifuged at 500 x g for 10 min at 4°C.  The pellet was kept on 
ice.  The cells were washed once with 500 µl ice-cold PBS and centrifuged as above.  The 
supernatant was discarded and the cells were resuspended in hypotonic cell lysis buffer [25 
mM HEPES (pH 7.5), 5 mM MgCl2, 5 mM EDTA, 5 mM DTT, 2 mM PMSF, 10 µg/ml 
pepstatin A and 10 µg/ml leupeptin] at a concentration of 107 cells/ml.  The cells were lysed 
by subjecting them to four cycles of freezing and thawing.  The cell lysates were centrifuged 
at 16 000 x g for 20 min at 4°C and the supernatant fraction was collected and assayed for 
caspase-3 activity.  The protein concentration for each cell extract was estimated by the 
Bradford protein assay (Sigma) using BSA as a standard.  A representative protein calibration 
curve is shown in Figure A9 (Appendix A). 
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5.2.7.2 Caspase-3 Assay Protocol 
The assays were performed in flat-bottom, black polystyrene 96 well plates.  Duplicate wells 
for blank, test sample and negative control reaction mixtures were prepared as described in 
Table 5.1.  The plate was covered with Parafilm® and incubated at 37°C for 30 min.  After 
30 min, 2 µl of 2.5 mM Ac-DEVD-AMC substrate was added to all the wells.  The plate was 
covered with Parafilm® and incubated at 37°C for 60 min.  The fluorescence of the 
reactions was measured at an excitation wavelength of 360 nm and an emission wavelength 
of 460 nm.  The specific activity was calculated as pmol AMC liberated/minute at 37°C/mg 
protein.  A representative AMC calibration curve is shown in Figure A10 (Appendix A).    
 
 
Table 5.1 Reaction mixtures as prepared for caspase-3 activity assays. 
 
                                                        Test         Negative 
                                                    Blank             sample              control 
 
Caspase Assay Buffer  32 µl  32 µl  32 µl 
DMSO      2 µl    2 µl     –  
DTT, 100 mM   10 µl  10 µl  10 µl 
Cell extract      –  10 µl  10 µl 
2.5 mM caspase-3 inhibitor     –    –    2 µl 
Deionised water    54 µl  44 µl  44 µl 
 
 
 
5.3  RESULTS AND DISCUSSION 
 
5.3.1 Phase-contrast Microscopy 
Within the population of cyclo(Phe-Pro)-treated cells (Figure 5.2B), some appeared rounded 
and detached from surrounding cells compared to the uniformity observed in untreated 
control cells (Figure 5.2A).  Desjardins and MacManus (1995) have described the “rounding” 
of cells, and detachment from neighbouring cells, as specific features of the apoptotic 
process in HT-29 cells.  Some cyclo(Phe-Pro)-treated cells appeared elongated (Figure 5.2B), 
a feature that has also been described as characteristic of apoptotic morphology 
(Darzynkiewicz et al., 1997).  
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Figure 5.2  Phase-contrast photomicrographs of HT-29 cells (original magnification = 400x). A, untreated 
control cells; B, cells treated with 5 mM cyclo(Phe-Pro) for 48 hours.  
 
5.3.2 Analysis of Chromatin Condensation  
Nuclear chromatin condensation is considered to be one of the hallmark events in apoptosis 
(Kerr et al., 1994).  DNA in condensed chromatin exhibits hyperchromasia, staining strongly 
with fluorescent dyes, compared to non-apoptotic cells (Darzynkiewicz et al., 1997).  
Hoechst 33342 staining of HT-29 cells showed that untreated control cells displayed normal 
staining of chromatin (Figure 5.3A).  By contrast, cells treated with 5 mM cyclo(Phe-Pro) for 
48 hours displayed hyperfluorescence of condensed chromatin and fragmented nuclei 
(Figure 5.3B) (Brauns et al., 2004).  The morphological features observed here are consistent 
with previous reports of cells undergoing caspase-dependent apoptosis (Leist and Jäättelä, 
2001), suggesting the activation of caspases by cyclo(Phe-Pro).  The results for the 
quantitative assessment of apoptosis are shown in Figure 5.4 (Brauns et al., 2004).  For the 5 
mM cyclo(Phe-Pro) treatment, apoptotic cells were first detected after 12 hours at less than 
4%, and this increased to 18.3 ± 2.85% (p<0.01) after 72 hours, compared to control cells in 
which 2.9 ± 1.03% of the cells was observed as apoptotic (Brauns et al., 2004).  The delay 
between addition of cyclo(Phe-Pro) and an increase in the proportion of apoptotic cells 
(Figure 5.4) is consistent with previous reports of apoptosis induction in a variety of cells 
(Faleiro et al., 1997, Kaufmann et al., 1993).            
      A  B  
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Figure 5.3  Photomicrographs showing HT-29 cells stained with Hoechst 33342 (original magnification = 
400x).  A, untreated control cells; B, cells treated with 5 mM cyclo(Phe-Pro) for 48 hours.   
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Figure 5.4 Percentage of apoptosis in cyclo(Phe-Pro)-treated HT-29 cells.  Fluorescence microscopy of 
Hoechst 33342-stained cells was used to evaluate the number of cells with condensed chromatin and 
fragmented nuclei.  Results are expressed as means ± SD of triplicate assays in one experiment, which is 
representative of three independent experiments. *, p<0.01; **, p<0.05 (compared to control cells). 
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5.3.3 Dual Staining with Hoechst 33342 and Annexin V-FITC  
During apoptosis, one of the classical alterations observed at the plasma membrane level is 
the translocation of PS from the inner layer to the outer layer, exposing PS at the external 
surface of the cell (Verhoven et al., 1995).  In the present study Hoechst 33342 was used in 
conjunction with annexin V-fluorescein to investigate nuclear and membrane changes 
simultaneously.  The results are shown in Figure 5.5.  Hoechst 33342 staining (Figure 5.5A) 
showed three cells with markedly condensed chromatin (indicative of apoptosis).  Annexin 
V-fluorescein staining (Figure 5.5B) showed that only these three apoptotic cells displayed 
significant binding of annexin V (indicative of PS externalisation) (Brauns et al., 2004). 
 
Necrotic or lysed cells may also expose PS according to the loss of membrane integrity 
(Darzynkiewicz et al., 1997).  To distinguish between apoptosis and potential necrosis, 
cyclo(Phe-Pro)-treated cells were concomitantly stained with annexin V-fluorescein and 
propidium iodide (PI).  No PI staining was observed among the annexin V-positive cells 
(data not shown), thus excluding the presence of necrotic or lysed cells in the population 
(Brauns et al., 2004).   
 
 
 
 
 
Figure 5.5  Photomicrographs showing the dual staining of HT-29 cells after treatment with 5 mM cyclo(Phe-
Pro) for 48 hours (original magnification = 400x).  A, Hoechst 33342 staining showing three cells with 
markedly condensed chromatin; B, Annexin V-fluorescein staining of the three apoptotic cells. 
 
 
 A B
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5.3.4 Detection of PARP Cleavage 
HT-29 cells were treated with 5 and 10 mM cyclo(Phe-Pro) for 24 and 48 hours.  Figure 5.6 
shows the resultant immunoblot for the detection of PARP cleavage.  The Mr 113 kDa band 
represented intact (uncleaved) PARP.  In control cells (lane 1), PARP remained uncleaved.  
There was no PARP cleavage detected in cells treated with 5 mM cyclo(Phe-Pro) for 24 or 
48 hours (lanes 2 and 3, respectively).  This result is seemingly incongruent with those 
reported in Figures 5.3 and 5.4 (section 5.3.2) for the 5 mM cyclo(Phe-Pro) treatment.  
However, this finding may reflect the inherent asynchronous nature of the apoptosis 
programme (Verhoven et al., 1995).  It should be noted here that the initiation of the cell 
death programme in most cases is not synchronous within a population so that the fraction 
of cells actually undergoing apoptosis at any time after stimulation may be quite small, and 
the fraction of cells engaging in a particular apoptotic event even smaller (Verhoven et al., 
1995).  Furthermore, apoptosis is a rapid process and the phenotype is transient (Kerr et al., 
1994).  Therefore, it may be speculated that the proportion of apoptotic cells present after 
treatment with 5 mM cyclo(Phe-Pro) for 24 or 48 hours, may be detectable by 
morphological assessment of individual cells (Figure 5.4, section 5.3.2), but may not be high 
enough to detect by western blot analysis of PARP cleavage (Figure 5.6, lanes 2 and 3).      
 
The appearance of a distinct Mr 24 kDa band in cells treated with 10 mM cyclo(Phe-Pro) for 
24 hours (lane 4), was indicative of caspase-dependent PARP cleavage (Nicholson et al., 
1995).  The appearance of the Mr 24 kDa band was concomitant with a decrease in intensity 
of the Mr 113 kDa band corresponding to intact PARP.  The presence of a Mr ~45 kDa 
band (lanes 1-4), was thought to be the result of non-specific binding to a protein that may 
have been abundant in the cell extracts.  After 48 hours of treatment with 10 mM cyclo(Phe-
Pro) (lane 5), levels of cleaved PARP (Mr 24 kDa) decreased, returning to those comparable 
with untreated cells.  However, the concomitant decrease in the level of uncleaved PARP in 
these cells (Mr 113 kDa, lane 5) suggests that PARP cleavage did occur.  It may thus be 
speculated that the absence of the Mr 24 kDa band in these cells (lane 5) could be attributed 
to further degradation of this band by cellular proteases.  Heerdt et al. (1999) reported a 
similar “loss” of PARP cleavage in MCF-7 cells after 24 hours of treatment with tributyrin, a 
triglyceride analogue of butyrate. 
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Figure 5.6  Immunoblot showing the detection of PARP cleavage in HT-29 cells treated with 5 and 10 mM 
cyclo(Phe-Pro) for 24 and 48 hours. Lanes: 1, untreated control cells; 2 and 3, 5 mM cyclo(Phe-Pro) for 24 and 
48 hours, respectively; 4 and 5, 10 mM cyclo(Phe-Pro) for 24 and 48 hours, respectively. 
 
 
In a subsequent set of experiments, HT-29 cells were treated with 10 mM cyclo(Phe-Pro) to 
investigate the progression of PARP cleavage at earlier time points up to 24 hours.  This was 
done to establish a time point for the onset of PARP cleavage in this study.  Cell extracts 
were obtained at 1, 4, 8 and 24 hours after exposure to 10 mM cyclo(Phe-Pro).  The 
resultant immunoblot is shown in Figure 5.7.  PARP remained uncleaved in untreated 
control cells (lane 1).  There was no PARP cleavage in cells treated with cyclo(Phe-Pro) for 1 
hour (lane 2).  The very faint signal at Mr 24 kDa, after 4 hours of cyclo(Phe-Pro) treatment 
(lane 3), is suggestive of PARP cleavage, but it is not definitive.  However, PARP cleavage 
was unequivocally detected as early as 8 hours following cyclo(Phe-Pro) treatment, 
demonstrated by the appearance of a faint band corresponding to the Mr 24 kDa cleavage 
fragment (lane 4).  After 24 hours PARP cleavage was almost complete (lane 5), shown by an 
intense Mr 24 kDa cleavage fragment, concomitant with an almost complete disappearance 
of the intact Mr 113 kDa PARP.  Interestingly, the intensity of the Mr ~45 kDa band 
appeared to increase with time, beyond 4 hours of exposure to cyclo(Phe-Pro).  Thus, it was 
suspected that the presence of the Mr ~45 kDa band was more than simply an artefact of 
non-specific binding.  
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Figure 5.7  Immunoblot showing the time course study of PARP cleavage in cyclo(Phe-Pro)-treated HT-29 
cells up to 24 hours.  Lanes: 1, untreated control cells; 2, 3, 4 and 5, cells treated with 10 mM cyclo(Phe-Pro) 
for 1, 4, 8 and 24 hours, respectively.  
 
 
 
5.3.5 The Effect of a Caspase Inhibitor on PARP Cleavage  
The broad-range caspase inhibitor, Z-VAD-FMK, was used to further evaluate the role of 
caspases in cyclo(Phe-Pro)-induced apoptosis.  The resultant immunoblot is shown in Figure  
5.8, demonstrating 10 mM cyclo(Phe-Pro)-induced PARP cleavage after 8, 12, 16 and 24 
hours of treatment (lanes 2, 4, 6 and 8, respectively).  Co-administration of Z-VAD-FMK 
inhibited the cyclo(Phe-Pro)-induced PARP cleavage in HT-29 cells at each time point, 
namely 8, 12, 16 and 24 hours (lanes 3, 5, 7 and 9, respectively).  These results strongly 
suggest that cyclo(Phe-Pro) treatment of HT-29 cells led to the induction of apoptosis 
involving caspase-3-like activity, consistent with previous reports of Z-VAD-FMK inhibition 
of drug-induced apoptosis (Pink et al., 2000; Ruemmele et al., 1999; Sun et al., 1999;  Wood et 
al., 1998). 
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Figure 5.8  Immunoblot showing the effect of the caspase inhibitor Z-VAD-FMK on cyclo(Phe-Pro)-induced 
PARP cleavage in HT-29 cells.  Lanes: 1, untreated control cells; 2, 4, 6 and 8, cells treated with 10 mM 
cyclo(Phe-Pro) for 8, 12, 16 and 24 hours, respectively; 3, 5, 7 and 9, cells treated with 10 mM cyclo(Phe-Pro) 
in the presence of inhibitor (50 µM) for 8, 12, 16 and 24 hours, respectively.  
 
 
Another important finding in this experiment was that the Mr ~45 kDa band was 
significantly less intense in cells treated with Z-VAD-FMK (Figure 5.8, lanes 3, 5, 7, and 9), 
compared to cells that received cyclo(Phe-Pro) in the absence of inhibitor (lanes 2, 4, 6 and 
8).  These results demonstrated that the appearance and variability of the Mr ~45 kDa band 
was not simply due to non-specific binding, but was related to cyclo(Phe-Pro)-induced, 
caspase-dependent PARP cleavage in HT-29 cells.  These results raised a number of 
interesting possibilities.  Firstly, the atypical pattern of PARP cleavage observed here 
(Figures 5.7 and 5.8) could be attributed to HT-29 cells undergoing late stage apoptosis 
(secondary necrosis).  A similar result was obtained by Shah et al. (1996), who reported the 
appearance of a minor degradation fragment of PARP at Mr ~ 47 kDa in drug-induced 
apoptosis in HL-60 human promyelomonocytic leukemia cells undergoing secondary 
necrosis.  On the other hand, there have been reports of the calcium-dependent protease, 
calpain, being activated in various models of apoptotic cell death, resulting in atypical PARP 
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cleavage (Pink et al., 2000; Wang, 2000).  It has been shown that the cleavage of PARP by 
calpain (specifically m-calpain) in vitro, yields fragments that range in Mr from 70 to 40 kDa 
(Wang, 2000).  In addition, it is known that calpain and caspase-3 share a number of dual 
substrates (Wang, 2000), and that both calpain and caspases can be activated by the same 
apoptotic stimulus in various cells (Ding et al., 2002; Blomgren et al., 2001; Waterhouse et al., 
1998).  Furthermore, Z-VAD-FMK is known to inhibit both calpains and caspases in drug-
induced apoptosis (Ding et al., 2002; Wood and Newcomb, 1999; Waterhouse et al., 1998).  
Therefore, it is likely that both calpains and caspases may be activated in cyclo(Phe-Pro)-
induced apoptosis in HT-29 cells.   
 
 
5.3.6 The Effect of a Calpain Inhibitor on PARP Cleavage  
The possible role of calpain activation in cyclo(Phe-Pro)-induced PARP cleavage in HT-29 
cells, was investigated by co-administration of the highly specific calpain inhibitor peptide 
and cyclo(Phe-Pro) for 8 and 12 hours.  The consistent presence of the Mr ~45 kDa and Mr 
24 kDa cleavage fragments indicated that the calpain inhibitor did not inhibit PARP cleavage 
(Figure 5.9).  It should be noted that the calpain inhibitor peptide is a reversible inhibitor 
(Maki et al., 1989).  Furthermore, this inhibitor is derived from the calpain inhibitory domain 
of calpastatin, the endogenous inhibitor of calpain (Maki et al., 1989), and it has been shown 
that caspase-3 is able to cleave calpastatin in neuronal cell death (Wang, 2000).  Therefore, 
further investigation would be required before calpain activation is ruled out as a plausible 
explanation for the atypical PARP cleavage observed in cyclo(Phe-Pro)-induced apoptosis in 
HT-29 cells. 
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Figure 5.9  Immunoblot showing the effect of calpain inhibitor peptide on cyclo(Phe-Pro)-induced PARP 
cleavage in HT-29 cells.  Lanes: 1, untreated control cells; 2 and 4, cells treated with 10 mM cyclo(Phe-Pro) for 
8 and 12 hours, respectively; 3 and 5, cells treated with 10 mM cyclo(Phe-Pro) in the presence of calpain 
inhibitor (50 µM) for 8 and 12 hours, respectively. 
 
 
 
5.3.7 Caspase-3 Activity Assay 
To confirm the immunoblot results for PARP cleavage, which demonstrated caspase-3 like 
activity, protein extracts taken from cyclo(Phe-Pro)-treated HT-29 cells after 8 and 12 hours, 
were analysed for caspase-3 activity.  The results are shown in Figure 5.10, illustrating a time-
dependent activation of caspase-3.  Since the fluorogenic substrate Ac-DEVD-AMC may be 
susceptible to cleavage by other related proteinases, the specific contribution of caspase-3 
activity was confirmed by using the inhibitor Ac-DEVD-CHO.  These results are consistent 
with previous reports of butyrate-induced apoptosis in LIM 1215 colorectal cancer cells, 
which showed caspase-3 activation within 16 hours of treatment (Medina et al., 1997).           
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Figure 5.10  Increase in caspase-3 activity during cyclo(Phe-Pro)-induced apoptosis in HT-29 cells.  Results are 
expressed as the mean ± SD of triplicate determinations, representative of three independent experiments. *, 
p< 0.01 compared to control cells.  NC, negative controls for lysates of untreated control cells and cells treated 
with cyclo(Phe-Pro) for 8 and 12 hours, incubated in the presence of the Ac-DEVD-CHO inhibitor. 
 
 
 
In summary, various methods for assessing different markers of apoptosis were used to 
show that cyclo(Phe-Pro) induced apoptotic cell death in HT-29 colon cancers cells. 
Morphological assessment using Hoechst 33342 staining showed that 5mM cyclo(Phe-Pro) 
induced characteristic chromatin condensation and nuclear fragmentation in HT-29 cells 
(Figure 5.3).  Furthermore, annexin V binding revealed that HT-29 cells treated with 5 mM 
cyclo(Phe-Pro), which showed apoptotic morphology, displayed PS externalisation after 48 
hours (Figure 5.5).  In addition, it was shown that 10 mM cyclo(Phe-Pro) induced 
characteristic PARP cleavage (Figure 5.7), one of the hallmark events of apoptosis (Boucher 
et al., 2001).  The use of the broad-range caspase inhibitor Z-VAD-FMK, showed that this 
PARP cleavage was caspase-dependent (Figure 5.8), which in turn was confirmed by 
demonstrating an increase in caspase-3 activity (p<0.01) in cyclo(Phe-Pro)-treated HT-29 
cells (Figure 5.10).  
 
 
 
 
 
  * 
     * 
 105
CHAPTER 6: GENERAL DISCUSSION 
 
 
Constrained peptides present simple and valuable models to gain insight into the three-
dimensional structure-bioactivity relationships of larger peptides and proteins (Anteunis, 
1978). Cyclic peptides have attracted considerable attention because of their limited 
conformational freedom and higher probability of conformational homogeneity when 
compared with their linear analogues (Toniolo, 1990).  The smallest cyclic peptides are 
dipeptides called diketopiperazines or cyclic dipeptides.  CDPs are simple and abundant in 
nature, common to synthetic, spontaneous and biological formation pathways (Prasad, 
1995).  They are detected naturally in marine sponges (Fu et al., 1998), microorganisms 
(Kanoh et al., 1999; Ström et al., 2002) and mammals (Prasad, 1995).  CDPs are also found in 
processed foods such as various cereal grains, cocoa, cheese and beverages including beer 
(Gautschi and Schmid, 1997) and roasted coffee (Ginz and Engelhardt, 2000).   
 
Although CDPs have been detected and studied as far back as the early 1900s, it is only in 
the last decade that their biological activity has attracted considerable interest (Prasad, 1995).  
Proline appears to be prevalent as a constituent amino acid among these biologically active 
CDPs.  For example, there have been reports of phytotoxic activity exhibited by cyclo(Tyr-
Pro) (Stierle et al., 1988), immunomodulation by cyclo(His-Pro) (Prasad, 1995; Fragner et al., 
1997), modulation of dietary fat intake by cyclo(Asp-Pro) (Lin et al., 1994), and antifungal 
activity exhibited by cyclo(Phe-Pro) (Ström et al., 2002).  Cyclo(Phe-Pro) and cyclo(Tyr-Pro) 
have also been implicated in the induction of differentiation in colon cancer cells (Graz et al., 
2000). Although some DKP-type metabolites have been isolated from various 
microorganisms as mycotoxins or antitumour agents, the antitumour potential of CDPs 
remains largely unexplored (Kanoh et al., 1999). 
 
The present study was therefore aimed at investigating the potential in vitro anticancer activity 
of selected proline-based CDPs against four human cancer cell lines, namely HT-29 (colon), 
HeLa (cervical), MCF-7 (breast) and WHCO3 (oesophageal).  The selection of cyclo(Phe-
Pro), cyclo(Tyr-Pro), cyclo(His-Pro), cyclo(Gly-Pro), cyclo(Pro-Pro), cyclo(Leu-Pro) and 
cyclo(Thr-Pro) (Figure 2.1, Chapter 2) was based on the inclusion of a representative group 
of proline-based CDPs with differing physicochemical properties in terms of their amino 
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acid side chains.  The selection of CDPs was also confined to the commercial availability, or 
availability of reliable methods of synthesis, of the relevant CDPs.  The effects of the CDPs 
on cell growth were determined by using the sulforhodamine B assay, which measures total 
protein content (Skehan et al., 1990) and the MTT assay, which measures ATP-mediated 
reduction of the tetrazolium dye (Alley et al., 1988).  The CDP that exhibited the highest 
growth inhibitory activity was used to investigate its potential to induce apoptosis in HT-29 
colon cancer cells.   
 
Most cancer therapies are known to induce cell death in tumour cells via apoptotic pathways 
(Huschtscha et al., 1996; Havrilesky et al., 1995; Shinomiya et al., 1994; Walker et al., 1991; 
Kaufmann, 1989).  Apoptosis, unlike necrosis, is a controlled physiological form of cell 
death in which a cell, given sufficient time, organizes a series of intracellular events that 
eventually leads to its destruction.  In the final stages of this death program the cell remnants 
are packaged into apoptotic bodies, avoiding inflammation in the surrounding normal tissues 
caused by necrotic cell lysis (Huppertz et al., 1999).  Apoptosis has thus attracted attention as 
a favourable pharmacodynamic end point of anticancer drug action (Au et al., 1997; Sellers 
and Fisher, 1999).  With the knowledge that links exist between pathways of cell 
proliferation, differentiation and apoptosis (Au et al., 1997; Hengartner, 1997), CDPs such as 
cyclo(Phe-Pro) and cyclo(Tyr-Pro), which have been implicated in the induction of 
differentiation in cancer cells, may show potential as anticancer agents whose effects on 
cancer cell growth may be linked to the induction of apoptosis in some cancer cells.        
 
In terms of the investigation into the effects on cell growth and viability, the results obtained 
in the present study showed that out of the seven CDPs, cyclo(Phe-Pro) exhibited the 
highest growth inhibitory effect (Figure 4.12, section 4.3.2, Chapter 4) (Brauns et al., 2004).  
The growth inhibition exhibited by cyclo(Phe-Pro) was shown to be dose-dependent (Figure 
4.23, section 4.3.6, Chapter 4) with an IC50 value of 4.04 ± 1.15 mM for HT-29 cells (Table 
4.1, section 4.3.6, Chapter 4).  It is interesting to note that some compounds that were 
originally classified as antimicrobial agents, e.g. actinomycin D and verticillin A, were later 
shown to be effective antitumour agents and subsequently classified as antitumour 
antibiotics (Rang et al., 1999).  Previous reports on the antifungal (Ström et al., 2002) and 
antibacterial (Graz et al., 1999) activity of cyclo(Phe-Pro), together with the results obtained 
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in the present study, suggest that cyclo(Phe-Pro) may be classified as an antitumour 
antibiotic. 
 
Interestingly cyclo(Tyr-Pro), which has a very similar structure to cyclo(Phe-Pro) (Figure 
3.16, section 3.5, Chapter 3), exhibited significantly less of an effect on cell growth (Figure 
4.24, section 4.3.6, Chapter 4).  Subtle structural differences are known to play a major role 
in the biological activity of some compounds.  For example, Kanoh et al. (1999), reported a 
33-100 fold difference in antitumour activity between the (+) and (–) enantiomers of the 
CDP derivative phenylahistin (Figure 1.3, section 1.2.5, Chapter 1), demonstrating that the 
stereochemistry of the α-carbon of the phenylalanine residue was important for the 
antitumour activity.  In the present study it is simply the presence of the hydroxyl group in 
cyclo(Tyr-Pro) that renders this compound more polar and less active against cancer cell 
growth than cyclo(Phe-Pro), with respect to the cell lines studied here. 
 
The growth inhibition exhibited by cyclo(Phe-Pro) in the present study, is of particular 
significance since cyclo(Phe-Pro) has been implicated in the induction of differentiation in 
HT-29 colon cancer cells (Graz et al., 2000).  Furthermore, it has been shown that the 
process of differentiation is closely linked to that of apoptosis (Hengartner, 2000; Huppertz 
et al., 1999; Au et al., 1997).  Accordingly, results in this study show, for the first time, that 
cyclo(Phe-Pro) induces apoptotic cell death in HT-29 colon cancer cells.  The apoptotic 
programme is characterised by particular morphological features such as chromatin 
condensation and nuclear fragmentation (Kerr et al., 1994).  As much as 18% of cells treated 
with 5 mM cyclo(Phe-Pro) for 72 hours showed condensed chromatin compared to less than 
3% in untreated control cells (Figure 5.4, section 5.3.2, Chapter 5) (Brauns et al., 2004).  The 
induction of apoptosis was confirmed, in part, by demonstrating the externalisation of PS in 
cyclo(Phe-Pro)-treated HT-29 cells (Figure 5.5, section 5.3.3, Chapter 5) (Brauns et al., 2004).  
These findings were consistent with previous results obtained for HT-29 cells treated with 
sulforaphane, a naturally occurring isothiocyanate (Gamet-Payrastre et al., 2000).  
 
The characteristic features of apoptosis-related chromatin condensation observed in the 
present study (Figure 5.3, section 5.3.2, Chapter 5) are suggestive of caspase activation in 
cyclo(Phe-Pro)-treated HT-29 cells.  These findings are consistent with the description of 
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this characteristic chromatin condensation as being indicative of apoptosis observed when 
caspases, particularly caspase-3, are activated, i.e. caspase-dependent cell death or apoptosis 
in its most classic form (Leist and Jäättelä, 2001).  Further evidence in support of caspase 
activation in the present study, was provided by demonstrating that cyclo(Phe-Pro) cleaved 
PARP to produce the characteristic Mr 24 kDa fragment (Figure 5.7, section 5.3.4, Chapter 
5), characteristic of caspase-dependent apoptosis (Nicholson et al., 1995).   
 
The use of the broad-range caspase inhibitor Z-VAD-FMK, which inhibited PARP cleavage 
(Figure 5.8, section 5.3.5, Chapter 5), confirmed the necessity of the caspase cascade in the 
execution of cyclo(Phe-Pro)-induced apoptosis in HT-29 cells.  These results are consistent 
with previous reports of Z-VAD-FMK inhibition of caspase-dependent PARP cleavage in 
drug-induced apoptosis (Pink et al., 2000; Sun et al., 1999; Ruemmele et al., 1999; Wood et al., 
1998).  There was, however, an apparent incongruity in the results obtained in the present 
study compared to previous reports on typical PARP cleavage (Nicholson et al., 1995); i.e. 
the consistent appearance of an unexpected Mr ~45 kDa fragment in addition to the 
characteristic Mr 24 kDa fragment (Figures 5.6 to 5.9, Chapter 5).  It is postulated that the 
atypical PARP cleavage exhibited by cyclo(Phe-Pro) is most likely due to either secondary 
necrosis as reported by Shah et al. (1996), or the activation of a non-caspase protease such as 
calpain (Pink et al., 2000; Wang, 2000).  Although the calpain inhibitor peptide  used in this 
study did not block the cyclo(Phe-Pro)-induced atypical PARP cleavage (Figure 5.9, section 
5.3.6, Chapter 5), the involvement of calpain cannot be completely ruled out as a possibility.  
Further investigation, in terms of a specific calpain activity assay or western blot analysis of 
calpain autolysis, should be conducted to confirm whether or not calpain is activated in 
cyclo(Phe-Pro)-induced apoptosis.  Both approaches have previously been used to 
demonstrate calpain activation in drug-induced apoptosis (Ding et al., 2002; Johnson, 2000).   
 
A third possibility that may account for the atypical PARP cleavage observed in the present 
study, is the activation of a protease distinct from caspases or calpains, particularly in the 
light of recent advances in the discovery of alternative and caspase-independent cell death 
pathways (Leist and Jäättelä, 2001).  For example, other non-caspase proteases that have 
been closely linked to apoptosis are cathepsins (Roberts et al., 1999), granzymes (Johnson, 
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2000), and the proteasome (Orlowski, 1999).  However, there have been no reports as yet of 
PARP cleavage by any of these proteases.  
 
The results showing increased caspase-3 activity in cyclo(Phe-Pro)-treated HT-29 cells 
(Figure 5.10, section 5.3.7, Chapter 5) confirm that caspase-3 is directly involved in the 
execution phase of cyclo(Phe-Pro)-induced apoptosis in HT-29 cells.  Although most 
caspases are able to cleave PARP to produce the characteristic cleavage fragments, caspase-3 
and -7 have attracted considerable attention because these enzymes have a much higher 
affinity for PARP, and caspase-3 in particular has been reported to be directly involved and 
essential in the execution phase of most forms of apoptotic cell death (Leist and Jäättelä, 
2001; Germain et al., 1999).    
 
The IC50 values for cyclo(Phe-Pro) (Table 4.1, section 4.3.6, Chapter 4) are much higher than 
those reported for most anticancer drugs, which are effective in the micromolar range 
(Huschtscha et al., 1996; Havrilesky et al., 1995; Shinomiya et al., 1994; Monks et al., 1991; 
Walker et al., 1991; Kaufmann, 1989).  The high CDP concentrations required for significant 
growth inhibition and induction of apoptosis could be due to a number of factors, including 
the possibility of CDPs binding to serum proteins in the growth medium (Taki et al., 1998), 
drug efflux by the multidrug transporter, P-glycoprotein (Bellamy, 1996), or the lack of 
sufficient absorption of peptide into the cells (Tamura et al., 1996).  Tamura et al. (1996) have 
reported that CDPs permeate Caco-2 cell monolayers (used as a model of the small intestine) 
primarily via a paracellular route, with minimal absorption of peptide into the cells.  In 
contrast to these findings, Mizuma et al. (2002) reported on the active transport of CDPs 
containing phenylalanine or tyrosine by the oligopeptide cotransporter (PEPT1).  However, 
these findings are mainly extrapolated to the possible mode of CDP transport in vivo, and do 
not necessarily relate to the absorption of CDPs in HT-29 cells.  Therefore, specific studies 
should be conducted in order to determine the kinetics of CDP uptake in HT-29 cells.  For 
example, the incorporation of a specific radioisotope into the CDP structure would yield a 
sensitive probe for the detection of CDPs in HT-29 cell cultures.   
 
The concentration of cyclo(Phe-Pro) (5 or 10  mM) that induced apoptosis in HT-29 cells in 
the present study is, however, comparable to that of a few compounds that show similar 
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activity in the millimolar range.  For example, sodium butyrate and aspirin have been shown 
to induce apoptosis in HT-29 colon cancer cells at concentrations of 5 mM (Heerdt et al., 
1994) and 3 mM (Qiao et al., 1998), respectively.  Furthermore, the apoptotic index (7.3 ± 
2.5%) (Figure 5.4, section 5.3.2, Chapter 5) for the 1mM cyclo(Phe-Pro) treatment, although 
not much higher than that of control cells (2.9 ± 1.03%), is also of biological relevance.  
According to Bursch et al. (1990) a measurable level of 3% apoptotic cells can result in tissue 
regression of 25% over several days if not balanced by proliferation.  Moreover, the 
application of the tools of rational drug design to cyclo(Phe-Pro)-related CDPs as lead 
compounds, may yield peptide drugs of greater specificity and efficacy that would 
circumvent the use of higher drug concentrations to achieve the desired effects.   
 
In summary, the results obtained in this study showed that cyclo(Phe-Pro) significantly 
inhibited the growth of HT-29, MCF-7, HeLa and WHCO3 cells, and induced apoptotic cell 
death in HT-29 cells, suggesting the potential to inhibit the growth of tumours in vivo 
(Bursch et al., 1990).  These findings warrant further investigation into the effects of 
cyclo(Phe-Pro) and related CDPs in the context of cancer chemoprevention or 
chemotherapy in humans.  In addition, the presence of appreciable levels of various proline-
based CDPs in a number of processed foods and beverages (e.g. 0.25 mM cyclo(Phe-Pro) in 
beer; Gautschi and Schmid, 1997), could suggest a paradigm shift from the general 
perception that most processed foods may be unhealthy for human consumption.  It may be 
speculated that the consumption of sufficient quantities of processed foods containing 
proline-based CDPs, could prevent the development of cancers within the gastrointestinal 
tract.  This conjecture would be substantiated if CDPs were indeed poorly transported 
across the intestinal epithelium as postulated by Tamura et al. (1996), implying that a 
significant quantity of the CDPs would not be absorbed in the small intestine, but be passed 
into the colon.  In the colon these CDPs may exert protective effects against the 
development of colorectal cancer. However, caution should be exercised before 
extrapolating the effects of cyclo(Phe-Pro) in vitro to its possible usefulness in humans.   
 
Further assessment is therefore required to determine the precise molecular targets of 
cyclo(Phe-Pro) in the induction of apoptosis in HT-29 colon cancer cells.  The present study 
showed that the execution caspase, caspase-3, is involved in cyclo(Phe-Pro)-induced 
apoptosis, but it is not certain which molecular events occur upstream of caspase-3 in this 
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model of apoptosis.  Furthermore, the initial trigger for cyclo(Phe-Pro)-induced apoptosis is 
unknown.  However, with the knowledge that caspase-3 was activated in the present study, it 
is postulated that cyclo(Phe-Pro) may trigger apoptosis via mitochondrial perturbation, with 
the subsequent release of cytochrome c and the activation of caspase-9.  This model would 
be consistent with most forms of drug-induced apoptosis (see Figure 1.6, section 1.4.2, 
Chapter 1).  It is therefore proposed that future work in this field should be directed towards 
investigating the processes related to the mitochondrial control of programmed cell death 
(PCD).  The term PCD is used here in order to include apoptosis as well as other forms of 
cell death that do not display the features of classical apoptosis, particularly in the light of the 
emergence of alternative cell death pathways (Leist and Jäättelä, 2001).  Many models of 
PCD involve some form of mitochondrial control, and it is useful to consider the signalling 
pathways upstream and downstream of these organelles separately (see Figure 6.1).  The pro-
apoptotic Bcl-2-related proteins, such as Bax, Bak, Bid and Bim, have a dominant role at the 
mitochondrial stage of PCD signalling.  The regulatory counterparts at this level include the 
anti-apoptotic members of this family (e.g. Bcl-2 and Bcl-xL).  Eventually, the ratio of death 
and survival signals sensed by the Bcl-2 family proteins determines whether the cell will live 
or die (Hengartner, 2000).   
 
Three pathways are triggered downstream of mitochondria (Figure 6.1).  The caspase 
pathway leading to classical apoptosis is initiated by the release of cytochrome c from the 
mitochondrial intermembrane space (Kroemer and Reed, 2000).  The second mitochondrial 
death pathway leads to necrotic PCD, without necessarily activating caspases.  The third 
pathway involves the release of the apoptosis-inducing factor (AIF) from the intermembrane 
space.  AIF induces caspase-independent formation of large (50 kb) chromatin fragments, 
whereas oligonucleosomal DNA fragments are generated only when caspase-activated 
DNase (CAD) is activated.  This biochemical difference is reflected by slight morphological 
differences in the shape of the condensed chromatin.  Often, more than one of these three 
pathways seem to be activated simultaneously.  The cell fate (and death mechanism) is then 
determined by the relative speed of each process in a given model system and by the 
antagonists of the individual pathways that are differentially expressed in different cell types 
(Leist and Jäättelä, 2001; Johnson, 2000). An appreciation of the subtleties of the 
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phenomenon of PCD warrants further investigation into the exact pathways that may be 
simultaneously triggered in cyclo(Phe-Pro)-induced apoptosis in HT-29 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1  Mitochondrial roles in programmed cell death.  Death triggers upstream of mitochondria usually do 
not require caspases. They include various chemotherapeutics, neurotoxins related to 1-methyl-4-
phenylpyridinium (MPP) or the retinal cytotoxic pigment A2E, and lipid mediators such as ceramide.  Most 
signals can be blocked by anti-apoptotic Bcl-2 family members or survival kinases that act on this level.  Three 
fundamentally different and initially independent signals emanate from mitochondria: a, Cytochrome c, which 
leads to caspase activation in the apoptosome and thus triggers classical apoptosis; b, Reactive oxygen species 
(ROS) and Ca2+, which induce necrotic PCD; c, the apoptosis inhibitory factor (AIF), which is released from 
mitochondria and triggers apoptotic-like death associated with chromatin condensation and margination, but 
not advanced chromatin compaction and nuclear fragmentation.  All three processes might feed back to 
mitochondria, affecting their function and structure, and therefore trigger one another.  Lack of essential 
cofactors for processes a and c will convert them to necrosis. Taken from Leist and Jäättelä (2001).   
 
 
Apart from the mitochondrial death pathways, it is conceivable that cyclo(Phe-Pro) could 
induce apoptosis via the receptor-mediated cell death pathway (see Figure 1.6, section 1.4.2, 
Chapter 1).  It has previously been shown that doxorubicin and other anticancer drugs 
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induce apoptosis that involves activation of the CD95 (Fas) system in leukaemia T cell lines 
and other tumour cells (Debatin, 1997).  
 
Further investigation into cyclo(Phe-Pro)-induced apoptosis could also include studies on 
the activation of caspase-7.  In some cases of drug-induced apoptosis, caspase-7 has been 
shown to have a higher affinity for PARP than caspase-3 (Germain et al., 1999).  In addition, 
the contributions of non-caspase proteases such as calpains, cathepsins and the proteasome 
could also be investigated.  In the case of calpains, Suc-Leu-leu-Val-Tyr-AMC, a membrane-
permeable calpain-specific fluorogenic substrate, may be used to assess calpain activation as 
described by Debiasi et al. (1999).  Calpain inhibitor I (N-acetyl-leucyl-norleucinol), a 
modified peptide that competes for the active site of calpain, may be used in negative control 
samples to verify calpain-specific activity (Debiasi et al., 1999).   
 
Finally, the lack of significant growth inhibition by 10 mM cyclo(Phe-Pro) and cyclo(Tyr-
Pro) in differentiated Caco-2 cells (Table 4.2, section 4.3.7, Chapter 4) is suggestive of 
selective toxicity of these CDPs towards transformed cells.  However, future work should 
include toxicity studies on a broad range of normal human cells to confirm the selectivity of 
these CDPs towards cancerous cells.  Nevertheless, CDPs such as cyclo(Phe-Pro) represent 
a unique group of compounds with interesting physicochemical properties and biological 
activity that suggest their potential as lead compounds in the development of peptide 
derivatives of therapeutic value.    
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APPENDIX:  ANALYTICAL DATA FOR CHAPTERS 3 AND 5 
 
 
 
 
          
 
 
Figure A1  Representative chromatogram for RP-HPLC detection of phenol. 
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Figure A2  Phenol calibration curve as determined by RP-HPLC analysis. (r2 = 0.998). 
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Figure A3  Representative chromatogram for RP-HPLC detection of cyclo(Phe-Pro). 
 
 
 
 
 
     
 
 
Figure A4  Representative chromatogram for RP-HPLC detection of cyclo(Tyr-Pro). 
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Figure A5 Overlay of the infrared spectra of cyclo(Phe-Pro) and cyclo(Tyr-Pro). 
 
 
 
 
       
 
 
Figure A6  1H (400.13 MHz) NMR spectrum of cyclo(Phe-Pro) in DMSO-d6. 
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Figure A7  1H (400.13 MHz) NMR spectrum of cyclo(Tyr-Pro) in DMSO-d6.  
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Figure A8  Calibration curve for the BCA protein assay using BSA as a standard. (r2 = 0.999). 
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Figure A9  Calibration curve for the Bradford protein assay using BSA as a standard. (r2 = 0.999). 
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Figure A10  AMC calibration curve for caspase-3 activity assay (r2 = 0.999). 
 
